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N E U R O - O N C O L O G Y
Abstracts
CELL BIOLOGY AND SIGNALING
CB-01. PTEN PHOSPHORYLATION BY FIBROBLAST GROWTH
FACTOR RECEPTORS AND SRC MEDIATES RESISTANCE
TO EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS
IN GLIOMA
Frank Furnari1, Timothy Fenton1, David Nathanson2, Claudio Ponte de
Alberquerque1, Daisuke Kuga2, Akio Wanami2, Julie Dang2, Huijun Yang2,
Kazuhiro Tanaka2, Lu Gao1, Sueli Oba-Shinjo3, Miyuki Uno3,
Maria-del-Mar Inda1, Robert Bachoo4, C. David James5, Ronald DePinho6,
Scott Vandenberg7, Huilin Zhou1, Suely Marie8, Paul Mischel2, and
Webster Cavenee1; 1Ludwig Institute-UCSD, La Jolla, CA; 2UCLA, Los
Angeles, CA; 3University of Sao Paulo, Sao Paulo, Brazil; 4University of
Texas Southwestern Medical Center, Dallas, TX; 5University of California–
San Francisco, San Francisco, CA; 6Dana-Farber Cancer Institute, Boston,
CA; 7University of California San Diego, La Jolla, CA; 8University of Sao
Paulo, Sao Paulo, CA
Glioblastoma multiforme (GBM) is the most aggressive of the astrocytic
malignancies and the most common intracranial tumor in adults. Although
the epidermal growth factor receptor (EGFR) is overexpressed and/or
mutated in at least 50% of GBM cases and is required for tumor mainten-
ance in animal models, EGFR inhibitors have thus far failed to deliver signifi-
cant responses in GBM patients. One inherent resistance mechanism in GBM
is the co-activation of multiple receptor tyrosine kinases (RTKs), which gen-
erates redundancy in activation of phosphoinositide-3’-kinase (PI3K) signal-
ing. Herein we present a novel mechanism by which fibroblast growth factor
receptors (FGFRs) and src family kinases (SFKs) impact PI3K signaling in
GBM by phosphorylating the PTEN tumor suppressor at a conserved tyro-
sine residue, Y240. Phosphorylation of Y240 is associated with shortened
overall survival and resistance to EGFR inhibitor therapy in GBM patients
and plays an active role in mediating resistance to EGFR inhibition in
vitro. Experimentally, mutation of PTEN tyrosine 240 to phenylalanine gen-
erates an allele of PTEN that potently sensitizes cells expressing mutant
EGFR to erlotinib. In contrast, activation of FGFR signaling promotes resist-
ance to erlotinib in glioblastoma cells expressing wild type PTEN, concor-
dant with phosphorylation of PTEN and activation of downstream
signaling. Together, our findings identify a novel signaling connection
between FGFRs and PTEN and provide a mechanistic link between PTEN
regulation and drug resistance, suggesting that blocking PTEN phosphoryl-
ation by suppression of src and/or FGFR activity represents a potential
strategy to re-sensitize tumors to EGFR inhibitors.
CB-02. GLIOBLASTOMA TUMOR MICROENVIRONMENT
DRIVES SELECTION OF CELL SUBPOPULATIONS WITH
DISTINCT RTK AMPLIFICATION GENOTYPES AND DRUG
SENSITIVITIES
Nicholas Szerlip1, Alicia Pedraza1, Jason Huse1, Tom Mikkelsen2, and
Cameron Brennan1; 1Memorial Sloan Kettering Cancer Center, New York,
NY; 2Henry Ford Hospital, Detroit, MI
INTRODUCTION: The majority of glioblastomas (GBMs) harbor ampli-
fication/mutation of a receptor tyrosine kinase (RTK), although clinical
trials of RTK inhibitors have shown inconsistent responses. One possible
mechanism of resistance is activation of multiple RTKs in a tumor. While
co-activation has been documented at the protein level in GBM, its signifi-
cance in maintaining cell populations is unknown. We investigated
whether amplification of two different RTKs can occur independently in
GBM tumor cell subpopulations, the mechanism of clonal evolution, and
the functional significance of genotype heterogeneity for pharmacologic
treatment. METHODS/RESULTS: ACGH profiles of 460 TCGA GBMs
and 150 tumors from MSKCC were examined for focal amplifications span-
ning EGFR, PDGFRA, and MET. Multicolor FISH was performed for
EGFR, PDGFRA, and cen7 for 8 coamplified cases. For two cases, derived
tumor sphere lines were expanded for study. Coamplification of 2 or more
RTKs was observed in 24 specimens. Remarkably, 43% of GBMs with
focal PDGFRA amplification also contained either EGFR or MET amplifica-
tions. FISH-demonstrated amplicons were primarily in distinct tumor cell
subpopulations, interspersed rather than regionally segregated. Expanded
cell lines from EGFR/PDGFRA coamplified tumors maintained distinct
RTK-driven subpopulations that were subject to selection under EGF or
PDGF ligand stimulation in vitro. Simultaneous inhibition of both EGFR
and PDGFR by gefitinib and imatinib was necessary to suppress PI3 kinase
pathway activation. Analysis of whole exome and whole genome sequencing
of coamplified TCGA samples and cell line subpopulations supports a
common clonal origin with late divergence of RTK-amplified clades,
although sequencing depth is limited. CONCLUSION: This is the first docu-
mentation of multiple subpopulations with distinct, high-level RTK amplifi-
cations in GBM. These results show certain GBMs commonly harbor
subpopulations with other RTK amplifications requiring drugs targeting
each subpopulation for effective treatment. This data should be considered
for current trials of RTK inhibitors, particularly those targeting PDGFR.
CB-03. SUR1-REGULATED NONSELECTIVE CATION CHANNEL
REPRESENTS A POSSIBLE NEW THERAPEUTIC TARGET
FOR GLIOMAS
Nicholas Szerlip1, Rudolph J. Castellani2, Svetlana Ivanova2, Volodymyr
V. Gerzanich2, and J. Marc Simard2; 1Memorial Sloan Kettering Cancer
Center, New York, NY; 2University of Maryland, Baltimore, MD
INTRODUCTION: Glioblastomas (GBMs) represent a broad and hetero-
geneous entity. Finding targeted tumor-specific treatments is a challenge.
One such target may be a novel channel formed by a protein complex con-
sisting of SUR1 regulatory subunits and TRPM4 pore-forming subunits.
This receptor/channel complex is not constitutively expressed but is upregu-
lated in CNS astrocytes during ischemic or inflammatory stress via transcrip-
tional activation of HIF-1alpha. When activated by natural ATP depletion or
pharmacologically with diazoxide, this complex initiates a cascade leading to
oncotic cell swelling and oncotic (necrotic) cell death that may be responsible
for central necrosis observed in GBM. The naturally hypoxic state of brain
tumors is expected to result in constitutive expression of this complex,
which may serve as a tumor-specific target for therapy. METHODS:
SUR1, TRPM4, and HIF-1alpha protein expression were examined by
immunohistochemistry in 21 paraffin specimens of high-grade glioma.
Normal brain specimens were used as controls. RESULTS:
Immunohistochemistry showed that SUR1 and TRPM4 were expressed in
all tumor specimens. Expression occurred broadly in normal support cells,
including endothelial cells and reactive astrocytes as well as in tumor cells.
In situ hybridization showed upregulation of ABCC8, the gene that
encodes the SUR1 protein. SUR1 expression colocalized with areas of
HIF-1alpha expression. In vitro luciferase assays confirmed that the human
ABCC8 promoter is effectively stimulated by HIF-1alpha. DISCUSSION:
This is the first report of the presence of the SUR1/TRPM4 channel
complex in GBM. This unique receptor complex represents a viable thera-
peutic target that is constitutively expressed in tumor tissue. We continue
to elucidate the role of this complex in possible treatment paradigms, to
exploit the cell death cascade controlled by this channel. Our data suggest
that this complex may serve as a novel, naturally occurring target for
pharmacological therapy that may be of benefit in GBM.
CB-04. MISMATCH REPAIR-INDEPENDENT DNA DAMAGE
DRIVES CHK1 ACTIVATION IN TEMOZOLOMIDE-TREATED
GBM CELLS
Motokazu Ito, Wendy See, Joydeep Mukherjee, Shigeo Ohba, I-Li Tan, and
Russell O. Pieper; University of California-San Francisco, San Francisco, CA
Temozolomide (TMZ) is a DNA methylating agent used in the treatment
of brain cancer. TMZ-induced O6-methylguanine (O6MG) adducts, in the
absence of repair by MGMT, mispair and trigger-futile mismatch repair
(MMR), delayed DNA double-strand breaks (DSB), Chk1 phosphorylation
(ser345)/activation, cell-cycle arrest, and ultimately cell death. Although
Chk1 activation is considered to be a downstream biomarker of MMR acti-
vation and DNA DSB, we noted elevated levels of pChk1 within 3 hours of
TMZ exposure in MGMT-proficient cells (G55 and U87 engineered to over-
express MGMT) as well as in their MGMT-deficient counterparts (U87 and
benzylguanine-treated G55 cells). Furthermore, even in the MGMT-deficient
cells, pChk1 levels peaked at 24 hours following TMZ exposure, long before
the onset (48 hours) of H2AX foci, DNA double-strand breaks, and
cell-cycle arrest. TMZ-induced pChk1 activation was also noted in
MGMT-depleted, MMR-deficient cells that exhibited neither H2AX foci
nor DNA DSB, dissociating pChk1 activation from MMR-driven processes.
TMZ-induced pChk1 activation was not a result of O6MG-induced
reactive-oxygen species (ROS) as ROS was not noted in MGMT-proficient
cells. TMZ-induced pChk1 activation was, however, temporally associated
with TMZ-induced alkali-labile DNA damage (ALD) detected by Comet
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assay. The transient ALD and Chk1 activation noted at early time points
(.12 hours post-TMZ exposure) in all cells was consistent with base exci-
sion repair of TMZ-induced N7-guanine and 3-methyl adenine DNA
adducts, while the persistent ALD and Chk1 activation noted at later time
points (,24 hours post-TMZ exposure) in MGMT-deficient cells was the
result of undefined, MMR-independent processing of TMZ-induced
O6MG lesions. These results redefine the series of events that activate the
DNA damage response following TMZ exposure and show that pChk1 is
a biomarker of TMZ-induced DNA lesions (in some cases O6MG lesions),
but not of their cytotoxic sequelae.
CB-05. HUMAN BRAIN-ENRICHED MICRO RNA-125B
(MIRNA-125B) INDUCES BOTH PROLIFERATION
AND SENESCENCE OF HUMAN ASTROGLIAL (HAG) CELLS
IN PRIMARY CULTURE
W.J. Lukiw1, Frank Culicchia2, Aileen Pogue1, Surjyadipta Bhattacharjee1,
and Yuhai Zhao3; 1Louisiana State University Neuroscience Center, New
Orleans, LA; 2Louisiana State University, Department of Neurosurgery,
New Orleans, LA; 3The University of Texas Health Science Center at
Houston, Houston, TX
microRNAs (miRNAs) represent a class of 22 nucleotide, noncoding,
single-stranded RNAs that regulate the stability, translation, and expression
of their target messenger RNAs (mRNAs). Of the approximately 1000
miRNAs known in human cells, only about 80 miRNAs are highly expressed
in human brain cells. Levels of a brain-abundant miRNA-125b, transcribed
from multiple genes at chr 11q24 and chr 21q21, are significantly upregu-
lated in cultured human glioma and glioblastoma cell lines and in
interleukin-6 (IL-6)-stressed normal human astroglial (HAG) cells; the
latter is a treatment known to trigger HAG cell proliferation. Herein we
report that miRNA-125b added to cultured HAG cells induces astrogliosis
and increases markers for senescence, including nuclear atrophy and
increased cytoplasmic/nuclear ratios. Anti-miRNA-125b (AM-125b) abro-
gated these induced effects. A strong positive correlation between the astro-
glial cell markers glial fibrillary acidic protein (GFAP) and vimentin and
miRNA-125b abundance was noted in biopsied human glioma and glioblas-
toma samples. These results suggest that miRNA-125b contributes to the
proliferation and premature aging of HAG cells, and that anti-miRNA
(AM; antagomir) strategies may be clinically useful in treating astroglial
cell proliferative disease. (Support: Translational Research Initiative
[LSUHSC-NO] and an Alzheimer Association IIRG Award [WJL])
CB-06. KNOCKDOWN OF CARBONIC ANHYDRASE IX
EXPRESSION IN MALIGNANT GLIOMA CELLS AUGMENTS
EFFICACY OF RADIATION AND CHEMOTHERAPY
Martin A. Proescholdt1, Marsha Merrill2, Eva Maria Störr1,
Annette Lohmeier1, and Alexander Brawanski1; 1University Regensburg
Medical Center, Regensburg, Germany; 2National Institutes of Health,
Bethesda, MD
OBJECTIVE: Concomitant radiochemotherapy is currently the standard
postsurgical treatment for glioblastoma. However, despite improvement of
radiation techniques and the advent of intensified chemotherapy dosage regi-
mens, virtually all patients display tumor recurrence. The hypoxia-inducible
carbonic anhydrase IX (CAIX) is highly expressed in glioblastoma, leading
to effective buffering of intracellular pH. Since transient acidification of
intracellular pH is required for the induction of apoptotic cell death, we
hypothesized that inhibition of CAIX expression may contribute to an
enhanced efficacy of radiation or chemotherapy. METHODS: U251 glioblas-
toma cells were transfected with a CAIX siRNA construct. A nonspecific
sequence siRNA served as control. The cells were incubated in a humidified
5% CO2 modular with either 21% oxygen and 25 mM glucose in the culture
medium (ctrl.) or 0% oxygen plus 125 mM glucose (glycolysis). Cells were
irradiated with 10 Gy; temozolomide treatment was performed at a concen-
tration of 50 mM. Suppression of CAIX expression by siRNA was investi-
gated by RTPCR and western blot. Cell toxicity was measured by a
colorimetric assay (AQ assay, Promega); apoptotic cell death was investi-
gated by annexin V labeling. ATP levels were measured using the Cell
Titer Glo kit (Promega). RESULTS: Transfection with sequence-specific
siRNA led to a 90% reduction of both CAIX mRNA and protein expression.
Knockdown of CAIX expression caused significantly lower ATP levels com-
bined with increased efficacy of radiation and chemotherapy, particularly
under glycolytic conditions. Annexin V labeling demonstrated a significantly
higher rate of apoptotic cell death upon CAIX knockdown in both treatment
arms compared to the nonspecific control. CONCLUSION: Our data
demonstrate that CAIX overexpression, which has been found in more
than 90% of all glioblastomas, reduces efficacy of adjuvant treatment such
as chemotherapy and radiation treatment. Blocking CAIX activity may
therefore be an additional target in glioblastoma treatment.
CB-07. EVALUATION OF THE HYPOXIA PATHWAY
IN PEDIATRIC AND ADULT EPENDYMOMAS
Shirley Abraham1, Randy Jensen2, and Soumen Khatua3; 1Primary
Children’s Medical Center, Salt Lake City, UT; 2Huntsman Cancer Institute,
Salt Lake City, UT; 3The University of Texas MD Anderson Cancer Center,
Houston, TX
The role of hypoxia-inducible factors (HIF) is well established in gliomas.
To date, its role in the development of ependymomas remains ill-defined.
This study for the first time intends to comprehensively evaluate key mol-
ecules of the HIF pathway in the oncogenesis of these tumors. Protein
expression of 5 major molecules of the HIF pathway (VEGF, CA9,
GLUT-1, HIF-1, and HIF-2) was evaluated by immunohistochemistry
(IHC) on 34 paraffin-embedded pediatric and 17 adult ependymoma
samples and normal control brain specimens. MIB-1 (proliferation index)
and microvascular density (MVD) were also analyzed on these samples.
Copy number analysis (CNA) using TaqMan copy number assay for the 5
molecules was performed. Results of the IHC analysis showed protein
expression (2+ to 4+) for VEGF, HIF-1, and CA9 correlating with higher
grades of tumor in greater than 80% of pediatric and adult ependymomas.
GLUT-1 and HIF-2 were expressed more strongly in pediatric ependymo-
mas. Normal brain tissues showed no protein expression for any of the mol-
ecules. The grade II and III pediatric ependymoma samples showed higher
MIB-1 and MVD indices than did their adult counterparts. There was no
statistically significant difference in the MIB-1 values of recurrent and non-
recurrent pediatric ependymomas. CNA showed deletion to be the major
aberration in the pediatric samples for all the target molecules except for
HIF-1 in which the role of amplification seemed to predominate. The
preliminary results of this study show for the first time the likelihood of
hypoxia-driven pathways inducing tumorigenesis in ependymomas. Gene
deletion of key molecules like VEGF and CA9 seems to be important in
the etiopathogenesis of this tumor formation. Further evaluation of the
hypoxia pathway and its signature molecules as potential therapeutic
targets is warranted in larger prospective studies.
CB-08. EXTRACELLULAR HSP90 IS A CENTRAL MEDIATOR
OF ONCOGENIC SIGNALING NETWORKS IN GLIOBLASTOMA
Udhayakumar Gopal1, Jinyan Du2, Frank He2, Todd Golub2, and Jennifer
S. Isaacs1; 1Medical University of South Carolina, Charleston, SC;
2The Broad Institute, Cambridge, MA
Glioblastoma multiforme (GBM) represents one of the most highly
aggressive brain tumors due to the propensity of tumor cells to invade
and migrate into surrounding normal brain tissue. It is precisely this infil-
trative behavior of GBM that renders the disease largely incurable. An
additional clinical challenge is the notorious genetic and molecular hetero-
geneity associated with this disease. As such, a main component of treat-
ment failure is elicited by the activation of multiple receptor kinases
(RTKs), which facilitates signaling redundancy and compensation upon
specific therapeutic RTK targeting. In terms of key signaling mediators,
AKT is frequently activated in human GBM, either due to loss of PTEN
or to RTK activation. We recently demonstrated that extracellular
Hsp90 (eHsp90), in tandem with its receptor LRP1, comprises a signaling
axis that is crucial for the stimulation and maintenance of AKT activation,
which in turn contributes to the promotility and aggressive behavior of
GBM. Given that the discovery of eHsp90 in GBM is completely new,
knowledge is lacking concerning its broader signaling effects and down-
stream targets. Therefore, in order to investigate the potential role of
eHsp90 in mediating signaling pathways in GBM, we have undertaken a
comprehensive analysis of the effects of eHsp90 inhibition upon nearly
all known cellular tyrosine kinases. Strikingly, we found that blockade
of eHsp90 signaling potently suppressed basal AKT activity and overrode
the ability of multiple growth factors to stimulate this kinase.
Furthermore, eHsp90 targeting also diminished the activation status of
several RTKs upon exposure to their respective ligands. Taken together,
our results support the notion that eHsp90 regulates an extensive RTK sig-
naling network that converges upon AKT function. Our results implicate
eHsp90 targeting as a potentially novel therapeutic approach that may
overcome some of the present challenges associated with RTK switching
upon the molecular targeting of specific signaling receptors.
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CB-09. CORTICOSTEROIDS IMPAIR GLIAL PROGENITOR CELL
FUNCTION IN THE CENTRAL NERVOUS SYSTEM
Jorg Dietrich1, Yannis Kalogirou-Valtis2, Ina Ly1, David Scadden1,
Chris Proschel3, and Margot Mayer-Proschel3; 1MGH – Harvard Medical
School, Boston, MA; 2Harvard University, Boston, MA; 3University of
Rochester School of Medicine, Rochester, NY
Corticosteroids, such as dexamethasone and methylprednisolone, are well
known for their powerful immunosuppressive, anti-inflammatory, and
anti-edematous effects, and are commonly used in the treatment of
autoimmune-inflammatory diseases and brain cancer. Despite their wide-
spread use in clinical practice, little is known about their effects on glial pro-
genitor cells and myelin integrity in the adult brain. The aim of the present
study was to determine the effects of commonly used corticosteroids on self-
renewal and differentiation of oligodendrocyte precursor cells (OPCs).
Primary cultures of purified OPCs were exposed to different concentrations
of corticosteroids. Cell proliferation and differentiation were determined by
BrdU-incorporation and immunohistochemical analysis both in mass cul-
tures and in clonal cultures. Corticosteroid treatment was associated with
a dose-dependent impairment of cell survival of OPCs and postmitotic oligo-
dendrocytes. Clonal studies revealed that corticosteroids were shifting the
balance between self-renewal and differentiation towards progenitor cell
differentiation. In vitro studies were predictive of in vivo studies, showing
impairment of glial progenitor proliferation in subcortical white mater
tracts of mice systemically exposed to methylprednisolone. Corticosteroid-
associated impairment of progenitor cell proliferation was in part reversed
by the powerful antioxidant N-acetylcysteine, suggesting a redox-dependent
steroid effect on neural progenitor cells. Given the critical importance of
neural progenitor cells for endogenous repair mechanisms, corticosteroid-
associated impairment of oligodendrocyte precursor cell function could
negatively influence myelination and repair processes in the adult central
nervous system.
CB-10. UNDERMINING SPARC-INDUCED PROSURVIVAL
SIGNALING THROUGH HSP27 IS A MORE EFFECTIVE
THERAPEUTIC STRATEGY THAN PROMOTING
SPARC-INDUCED, TEMOZOLOMIDE (TMZ)-ASSOCIATED
PRODEATH SIGNALING IN GLIOMA CELLS
Sandra A. Rempel, Chad R. Schultz, William Golembieski, and
Chaya Brodie; Henry Ford Hospital, Detroit, MI
SPARC promotes invasion through pHSP27 upregulation and promotes
survival via AKT activation, suggesting it is a therapeutic target. Because
pHSP27 also upregulates pAKT, we proposed that suppressing HSP27
could inhibit SPARC-induced survival. Alternatively, published data
suggest SPARC is a chemosensitizer. Therefore, we assessed the effects of
SPARC expression+TMZ or SPARC inhibition and downstream HSP27
inhibition to assess its role as a therapeutic agent versus target. 1) Control-
and SPARC-expressing U87 cells or LN443 cells treated with control,
SPARC, HSP27, or AKT siRNAs+TMZ were subjected to western blot
analyses. Quantitation was performed (ImageJ [n ≥ 3]). Two-fold changes
were considered significant. 2) The cells were also subjected to clonogenic
assays to assess survival (n ≥ 2). Results indicate: 1) SPARC promotes pro-
survival (HSP27, AKT) and prodeath (caspase 8, cleaved caspase 3) signal-
ing, and SPARC and control cells survive similarly. 2) TMZ activates
autophagy in both control and SPARC-expressing cells, but SPARC sensi-
tizes cells to apoptotic signaling (cleaved caspase 7 and PARP). Despite
increased apoptotic signaling, SPARC-expressing cells survive better in
TMZ (p ¼ 0.0001). 3) SPARC siRNA suppresses TMZ-induced caspase 7
and PARP cleavage and LC3-II, does not affect survival in TMZ, and para-
doxically enhances survival in the absence of TMZ (p ¼ 0.018). 4) AKT1/2/
3 siRNA treatments mimic SPARC siRNA effects (p ¼ 0.003), except AKT3
siRNA does not affect survival in the absence of TMZ. 5) HSP27 siRNA sup-
presses SPARC and AKT and suppresses survival (p ¼ 0.0001) but does not
further sensitize cells to TMZ. In conclusion, SPARC or AKT inhibition is
not effective therapy as inhibition promotes survival, and inhibition in
TMZ has a minor effect on survival. Although HSP27 inhibition does
not sensitize cells to TMZ, suppression effectively decreases survival.
Therefore, suppressing HSP27 is therapeutically more effective than promot-
ing SPARC-induced, TMZ-associated prodeath signaling.
CB-11. DECREASED MIR-218 EXPRESSION PROMOTES TUMOR
CELL SURVIVAL PATHWAYS IN GLIOBLASTOMAS
Lijoy K. Mathew1, Nicolas Skuli1, Vera Mucaj1, Hongxia Z. Imtiyaz1,
Sriram Venneti1, Priti Lal1, Zhongfa Zhang2, Ramana V. Davuluri2,
Cameron Koch1, Sydney Evans1, and M. Celeste Simon1; 1University of
Pennsylvania, Philadelphia, PA; 2Wistar Institute, Philadelphia, PA
Glioblastoma multiforme (GBMs) are primary malignant brain tumors
with a median survival of approximately 12-14 months. Recently, it has
been reported that numerous microRNAs are differentially expressed in
GBMs when compared with adjacent non-neoplastic brain tissue. Among
these, miR-218 is expressed at significantly lower levels in GBMs compared
to adjacent normal neurons. Our functional analyses indicated that miR-218
overexpression increases sensitivity to cell death and reduces cell invasion
capacity. Since miR-218 overexpression sensitizes tumor cells to apoptotic
stimuli. Temozolomide (TMZ), a widely used chemotherapeutic agent for
human GBM patients, was utilized in an orthotopic xenograft brain tumor
assay. Mice injected with control (U87-NS) or miR-218 overexpressing
human glioblastoma cells (U87-218) developed intracranial orthotopic
tumors without a significant difference in survival rate (20 days). TMZ
delivered to the U87-NS group increased survival up to an average of 45
days. However, the combinatorial use of miR-218 and TMZ significantly
increased survival, and 50% of animals failed to develop tumors even after
288 days of treatment. ECOP, PLCg1, and NAC-1 were identified as
direct miR-218 targets and experimentally validated. Repression of ECOP
and PLCg1 in GBM cells resulted in increased sensitivity to cell death,
suggesting these genes as contributors to miR-218 effects on cell survival.
Cell death mediated by increased miR-218 expression was not restored
with PLCg1 over-expression alone; however, reduced cell invasion was com-
pletely rescued with PLCg1. Since PLCg1 modulates PKC and NF-kappaB
pathways, we analyzed and identified that miR-218 overexpression inhibits
these cell survival pathways, indicating the role of PLCg1. Our analysis of
human GBM patient samples identified a reciprocal correlation between
the expression of miR-218 and target genes. Finally, bioinformatic analysis
revealed that low miR-218 expression correlates with poor patient survival
with a mesenchymal gene signature. Altogether, these studies clearly reveal
a critical role for miR-218 in GBM tumorigenesis.
CB-12. A SURVEY OF HUMAN CYTOMEGALOVIRUS GENOMIC
LOCI PRESENT IN GLIOBLASTOMA MULTIFORME TISSUE
SAMPLES
Padhma Ranganathan, Paul Clark, Shahriar Salamat, John S. Kuo, and
Robert F. Kalejta; University of Wisconsin-Madison, Madison, WI
Human cytomegalovirus (HCMV) causes CNS disorders, birth defects,
and immunological complications and has been recently associated with
glioblastoma multiforme (GBM) based on the detection of selected viral
DNA segments, mRNAs, and protein antigens in tumor tissues. GBM is
the most common form of malignant brain tumor and is highly refractive
to various treatment options, resulting in a high rate of recurrence and mor-
tality. A greater insight into the mechanism of tumorigenesis and identifi-
cation of specific oncogenic agents or oncomodulatory factors is necessary
to develop better therapeutic alternatives. HCMV is a good oncogenic can-
didate for glioma genesis as many viral gene products are capable of control-
ling protooncogenic cellular processes such as differentiation, proliferation,
inflammation, migration, and angiogenesis in addition to conferring resist-
ance to chemotherapy. However, it is not known if these specific HCMV
genes are expressed in GBMs. In fact, no reported studies have examined
whether the entire 235 kilobase double-stranded DNA viral genome or
only select viral genes are retained in these tumors. In order to specifically
identify regions of the HCMV genome maintained in GBMs, we generated
primers for 15 loci spaced at regular intervals along the viral genome and
standardized the assay to detect viral DNA in tumor tissues by PCR. We
then obtained 75 GBM biopsy samples and 30 controls comprising of both
nontumor and nonglioma tumor tissues. DNA extracted from these tissues
has been examined for the presence of viral DNA by PCR. Additionally,
we analyzed a set of 12 surgical tissue samples as well for HCMV DNA.
We report that altogether the incidence of HCMV DNA in GBM is higher
compared to that in the controls. This analysis provides the first evidence
of the extent to which the HCMV genome is found in GBM. Future work
would characterize the expression pattern of HCMV genes in GBM.
CB-13. GENOMIC ANALYSIS OF CYTOMEGALOVIRUS
IN MALIGNANT GLIOMAS
Bornali Bhattacharjee, Nicholas Renzette, Richard P. Moser, and Timothy
F. Kowalik; University of Massachusetts Medical School, Worcester, MA
Studies show that most malignant gliomas are infected with cytomegalo-
virus (CMV). However, the genetic status, including DNA loads and
genetic and genomic sequences of CMV in tumors has not been examined.
CMV DNA was found in 16/17 (94%) tumor specimens. Viral DNA
loads ranged from .10e2-10e6 copies/500ng of total DNA with a median
log 10 viral load of 4.0 (+1.6). DNA loads did not correlate with tumor
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grade. These viral DNA loads are low relative to DNA levels found in pro-
ductive infections and suggest that CMV is not replicating in the tumors.
Viral genes associated with all phases of CMV replication were expressed
in tumor samples, but expression levels were not linked to viral DNA
loads. These observations suggest that atypical infections occur in tumors.
The viral UL83 gene, encoding pp65, was sequenced to determine whether
specific sequences associate with tumor grade and because most anti-CMV
T cell responses are directed against the protein. UL83 sequence networks
suggest that GBMs and lower grade gliomas segregated away from each
other, with amino acid changes observed in each GBM. To better understand
the genomic nature of CMV in GBM, .80 kbp of the CMV genome was
sequenced and analyzed. Sequence analysis revealed that a unique CMV
strain exists in this tumor. Deep sequencing uncovered a viral population
that was less variable (p ¼ 0.1% and pAA ¼ 0.08%) than that observed
in productive infections. In addition, 56/60 viral genes analyzed had
dN/dS scores of ,1, indicative of high sequence conservation. In conclusion,
CMV DNA levels, while variable, result in readily detectable gene
expression, but the virus does not appear to replicate in tumors. Gene level
analyses suggest sequence biases separate low- and high-grade gliomas.
Finally, near genome-scale sequencing of CMV indicates that a unique
viral sequence is present in a GBM and pressures exist to retain CMV
sequence information.
CB-14. THERAPEUTIC POTENTIAL OF AZD1480
FOR THE TREATMENT OF HUMAN GLIOBLASTOMA
Braden C. McFarland1, Jing-Yuan Ma1, Catherine P. Langford1,
G. Yancey Gillespie1, Hao Yu1, Ying Zheng1, Susan E. Nozell1,
Dennis Huszar2, and Etty N. Benveniste1; 1University of Alabama at
Birmingham, Birmingham, AL; 2AstraZeneca R&D Boston, Waltham, MA
Aberrant activation of the janus kinase (JAK)/signal activator of transcrip-
tion (STAT) pathway has been implicated in glioblastoma (GBM) pro-
gression. STAT-3 is persistently activated in human GBM samples, which
correlates with elevated levels of many STAT-3 target genes that promote
tumor progression. To develop a therapeutic strategy to inhibit STAT-3 sig-
naling, we have evaluated the effects of AZD1480, a pharmacological inhibi-
tor of JAK1 and JAK2. AZD1480 treatment inhibits the growth of multiple
tumor types, but the effect on GBM tumors has not been reported. In this
study, the in vitro efficacy of AZD1480 was tested in human and murine
glioma cell lines. AZD1480 treatment effectively blocks constitutive and
stimulus-induced JAK1, JAK2, and STAT-3 phosphorylation in both
human and murine glioma cells and leads to a decrease in cell proliferation
and induction of apoptosis. Furthermore, we utilized human xenograft
GBM samples as models for the study of JAK/STAT-3 signaling in vivo. In
these xenograft tumors, JAK2 and STAT-3 are constitutively active, but
levels vary among tumors, which is consistent with the heterogeneity of
GBMs. AZD1480 inhibits constitutive and stimulus-induced phosphoryl-
ation of JAK2 and STAT-3 in these GBM xenograft tumors in vitro down-
stream gene expression and inhibits cell proliferation. Furthermore,
AZD1480 suppresses STAT-3 activation in the stem cell population in
GBM tumors. In vivo, AZD1480 inhibits the growth of subcutaneous
tumors and increases survival of mice bearing intracranial GBM tumors by
inhibiting STAT-3 activity. However, we found that xenograft tumors that
display EGFR amplification are less sensitive to AZD1480 therapy, indicat-
ing EGFR status may be an important determinant of responsiveness to
AZD1480 and will need to be considered in future studies. Overall, our
data indicate that pharmacological inhibition of the JAK/STAT-3 pathway
by AZD1480 should be considered for study in the treatment of patients
with GBM tumors.
CB-15. beta3-ADRENERGIC AGONISTS MIMIC EUSTRESS
RESPONSE AND REDUCE LEPTIN-MEDIATED
PROLIFERATION IN A GBM CELL LINE
Johnathan E. Lawrence1, Nicholas J. Cook2, Richard A. Rovin3, and Robert
J. Winn1; 1Northern Michigan University, Marquette, MI; 2Upper Michigan
Brain Tumor Center, Marquette, MI; 3Marquette General Hospital,
Marquette, MI
A great deal of mental stress, depression, and anxiety often overwhelm
cancer patients; those diagnosed with glioblastoma multiforme (GBM) are
no exception. Different types of stress invariably impact what has been
termed “the brain-adipocyte BDNF/leptin axis” (Dr. Cao and colleagues
of the Comprehensive Cancer Center at The Ohio State University). For
example, eustress (good stress) and distress (bad stress) both lead to increased
sympathetic activity and adrenal gland stimulation, yet eustress reduces
leptin levels and attenuates tumor growth while distress increases leptin
levels and augments tumor growth. Complicating matters in GBM is that
leptin and its receptor are expressed at much higher levels than in normal
glial cells and provides a potential autocrine signaling pathway. In this
study, we confirm that 200 ng/mL of leptin-conditioned media increases
cell proliferation of the established GBM cell line T98G. We hypothesized
that elevated sympathoadrenal activity would increase cell proliferation
and be additive to leptin’s effects. To the contrary, adding 300 pg/mL of epi-
nephrine to leptin-conditioned media blocked leptin-mediated proliferation.
Because beta3-adrenergic receptor stimulation suppresses leptin gene
expression and release in adipocytes, we hypothesized that a beta3-
adrenergic agonist would counteract leptin’s effects on T98G cell
proliferation. Use of the beta3-adrenergic agonist BRL 37344 did not only
counteract leptin’s effects but also significantly reduced T98G cell prolifer-
ation in unconditioned media. This has immediate translational value in
that treating GBM with a beta3-adrenergic agonist may reduce tumor
proliferation through receptor activation and by blocking the leptin-leptin
receptor autocrine loop. Moreover, recent reports indicate that
beta3-adrenergic agonists capable of crossing the blood-brain barrier (like
SR 58611A) may be beneficial for anxiety and depression, further improving
the quality of life for brain tumor patients.
CB-16. STRESS-REGULATED EXPRESSION OF MIR-451
CHANGES MIGRATORY AND PROLIFERATIVE PROPERTIES
OF GLIOMA CELLS IN VITRO AND IN VIVO: IMPLICATIONS
FOR THERAPEUTIC RADIOTHERAPY AND CHEMOTHERAPY
RESPONSE
Jakub A. Godlewski, Daisuke Ogawa, Agnieszka Bronisz, Sean Lawler, and
E. Antonio Chiocca; Ohio State University, Columbus, OH
GBM is characterized by rapid proliferation, angiogenesis, hypoxia, and
necrosis at the primary site, yet a small portion of the tumor invades and infil-
trates into normal brain parenchyma. Tumor cells in response to this challen-
ging and dynamic microenvironment face hypoxia, acidity, and limited
nutrient availability as the tumor grows. Glioma cells often utilize glycolysis,
which requires sufficient glucose and facilitates rapid cell growth. Cancer
cells ensure an adequate glucose supply through increased angiogenesis
and migration; but in rapidly growing tumors such as GBM, where
glucose availability may fluctuate, cells must engage adaptive strategies to
survive periods of metabolic stress. We previously identified a single
microRNA (miR-451) that controls glioma cell proliferation, migration,
and responsiveness to glucose deprivation through modulating activity of
the LKB1/AMPK signaling axis. This allows cells to survive metabolic
stress and to seek out favorable growth conditions. In the current study,
we show that the expression of miR-451 is regulated by stress, as we were
able to demonstrate profound effect of glucose withdrawal, radiotherapy,
and chemotherapy (temozolomide). We also discuss the role of upstream
stress-responsive transcription factors having their binding sites in close
proximity to miR-451 genomic locus. To address how miR-451 modulates
glioma cell invasiveness in vivo, we performed series of experiments
co-injecting invasive (+/2 miR-451) and non-invasive cells into nude
mice intracranially. We demonstrate that miR-451 expressing cells have
severely limited invasive phenotype, which is consistent with in vitro find-
ings. We believe that our in vivo model is highly relevant as it recapitulates
clinical characteristics of glioblastoma: highly proliferative tumor core
co-existing with highly invasive sub-population of cells; and as such is valu-
able tool to explore glioma biology. The dynamic regulation of microRNAs
in response to fluctuating glucose levels in the glioblastoma microenviron-
ment is essential for rapid tumor growth and dissemination and is revealing
novel targets for therapeutic intervention.
CB-17. MITOSIS INTERFERENCE OF CANCER CELLS DURING
ANAPHASE BY ELECTRIC FIELD FROM NOVOTTF-100A
Sze Xian Lee, Eric T. Wong, and Kenneth D. Swanson; Beth Israel Deaconess
Medical Center, Boston, MA
Chemotherapy and radiation initiate cancer cell death by triggering
defined cell cycle checkpoints. Unlike these treatments, the NovoTTF-
100A device, which is approved for the treatment of recurrent glioblastoma,
kills tumor cells by a novel mitosis interference mechanism. Our research has
revealed that the electric field (TTField) affects processes during mitosis
proximal to the point of the metaphase to anaphase transition, leading to
cell cycle arrest and ultimately cell death. Time-lapse movies of cells
exposed to the TTField revealed membrane blebbing and oscillation that
was initiated near the time of metaphase to anaphase transition. In synchro-
nous cell cultures exposed to the TTField, phospho-histone H3 was elevated
while securin levels were decreased, suggesting that cells exposed to the
TTField pass through the metaphase to anaphase transition but may be
delayed in mitotic exit. Immunofluorescence of cells treated with TTField
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for increasing periods of time showed disordered separation of chromosomes
from metaphase plates accompanied by lagging chromosomes, dispersion of
chromosomes from the metaphase plate, chromosomes decondensation in
the absence of cytokinesis, and daughter cells with asymmetric chromosomal
segregation, with derangement of cells increasing with the time of exposure.
These data suggest that TTField exposure resulted in perturbation of pro-
cesses following entry into anaphase and interfered with processes necessary
for orderly exit from mitosis. Furthermore, cells exposed to TTField showed
no detectable p53 induction, indicating that cell death is achieved by a
p53-independent mechanism. NovoTTF-100A appears to effect cell death
by interference with the mitotic apparatus that differs from currently used
spindle poisons and therefore may have synergism when combined with con-
ventional cancer treatments. (Supported in part by a grant from NovoCure,
Inc. and A Reason To Ride research fund.)
CB-18. SHP-2/PTPN11 MEDIATES GLIOMAGENESIS DRIVEN
BY PDGFRA AND INK4A/ARF ABERRATIONS IN MICE
AND HUMANS
Kun-wei Liu1, Haizhonog Feng1, Robert Bachoo2, Andrius Kazlauskas3,
Erin M. Smith4, Karen Symes4, Ronald L. Hamilton1, Motoo Nagane5,
Ryo Nishikawa6, Bo Hu1, and Shi-Yuan Cheng1; 1University of Pittsburgh,
Pittsburgh, PA; 2University of Texas Southwestern Medical Center, Dallas,
TX; 3Schepens Eye Research Institute and Harvard Medical School, Boston,
MA; 4Boston University, Boston, MA; 5Kyorin University, Tokyo, Japan;
6Saitama Medical University, Saitama-ken, Japan
Human gliomas account for the most common and malignant tumors in
the central nervous system. Despite intensive treatments, including
maximal surgical resection combined with radiotherapy and concurrent or
adjuvant chemotherapies, median survival time of patients with high-grade
glioblastoma multiforme (GBM) remains 14-16 months after diagnosis.
Recently, coordinated genomic analyses of a large cohort of clinical GBM
specimens have subclassified malignant glioblastomas into 4 clinical relevant
subtypes based on their signature genetic lesions. PDGFRA overexpression is
concomitant with a loss of CDKN2A locus (encoding P16INK4A and
P14ARF) in a large number of tumors within one subtype of glioblastomas.
Here, we report that activation of PDGFRalpha confers tumorigenicity to
Ink4a/Arf-deficient mouse astrocytes and human glioma cells in the brain.
Restoration of p16INK4a but not p19ARF suppresses PDGFRalpha-
promoted glioma formation. Mechanistically, abrogation of signaling
modules in PDGFRalpha that lost capacity to bind to SHP-2 or PI3K signifi-
cantly diminished PDGFRalpha-promoted tumorigenesis. Furthermore,
inhibition of SHP-2 by shRNAs or pharmacological inhibitors disrupted
the interaction of PI3K with PDGFRalpha, suppressed downstream AKT/
mTOR activation, and impaired tumorigenesis of Ink4a/Arf-null cells,
whereas expression of an activated PI3K mutant rescued the effect of
SHP-2 inhibition on tumorigenicity. In clinical glioblastoma specimens,
PDGFRalpha and PDGF-A are co-expressed and such co-expression is
linked with activation of SHP-2/AKT/mTOR-signaling. Together, our
data suggest that in glioblastomas with Ink4a/Arf deficiency, overexpressed
PDGFRalpha promotes tumorigenesis through the PI3K/AKT/
mTOR-mediated pathway regulated by SHP-2 activity. These findings
functionally validate the genomic analysis of glioblastomas and identify
SHP-2 as a potential target for treatments of glioblastomas with PDGFRA
overexpression.
CB-19. FUNCTIONAL CHARACTERIZATION OF MICRORNAS
IN PDGF-DRIVEN GLIOMAS
Joachim Silber, Anders Jacobsen, Tatsuya Ozawa, Girish Harinath,
Cameron W. Brennan, Eric C. Holland, Chris Sander, and Jason T. Huse;
Memorial Sloan-Kettering Cancer Center, New York, NY
MicroRNAs (miRNAs) are a class of small, noncoding RNAs that regulate
gene expression on a pretranslational level by binding loosely complemen-
tary sequences in target mRNAs. Each miRNA likely represses numerous
mRNA targets, and this promiscuity speaks to the ability of individual
miRNAs to mediate complex biological phenotypes. Recent comprehensive
genomic analyses have emphasized the importance of receptor tyrosine
kinases (RTKs) and their downstream signaling cascades in the process of
gliomagenesis. Among these, the platelet-derived growth factor (PDGF)
pathway appears to play a crucial role in the initiation and maintenance of
both low- and high-grade diffuse gliomas. An improved understanding of
how PDGF signaling mediates its oncogenic effects and the mechanisms
for its regulation would be of obvious benefit to the development of effective
targeted therapies. Based on an analysis of miRNA involvement in the phe-
notypic expression and regulation of oncogenic PDGF signaling, we have
identified a group of miRNAs whose expression levels are responsive to
PDGF pathway activation in vitro and have recapitulated these findings in
human glioblastomas, particularly those driven by aberrant PDGF signaling.
Similarly, using data from The Cancer Genome Atlas (TCGA), we found that
these microRNAs are differentially expressed in gliomas with amplification
of PDGFRA and/or in tumors of the proneural subtype compared to other
tumors in TCGA. By transiently and constitutively changing miRNAs
levels in gliomasphere cells, we have demonstrated that miRNAs from this
group specifically affect growth of PDGF driven gliomas, whereas the
same miRNAs have no effect on non-PDGF driven gliomas. We are now
evaluating the functional properties of these miRNAs in a variety of in
vivo systems and are investigating the mRNA targeting profiles of each
using a combination of differential protein expression, mRNA expression
arrays, and bioinformatics.
CB-20. CXCR4 ACTIVATION DEFINES A NEW SUBGROUP
OF SONIC HEDGEHOG DRIVEN MEDULLOBLASTOMAS
Rajarshi Sengupta1, Adrian Dubuc2, Stacey Ward1, Lihua Yang1,
Paul Northcott2, Kristin Kroll1, Michael Taylor2, Robert Wechsler-Reya3,
and Joshua Rubin1; 1Washington University, St. Louis, MO; 2University of
Toronto, Toronto, ON, Canada; 3Sanford-Burnham Medical Institute,
La Jolla, CA
Medulloblastoma is the most common malignant brain tumor of child-
hood. Despite aggressive multimodal therapy, overall survival rates remain
less than 70%, and survivors often suffer from severe neurologic, cognitive,
and endocrine side effects. The development of new and improved therapies
may be facilitated by molecular subgrouping of disease in which the primary
drivers of malignant growth are distinguished and the cell(s) of origin are
identified. Recent gene expression profiling has revealed 4 distinct subtypes
characterized by dysregulation in either WNT, sonic hedgehog (SHH),
Myc, or an as yet unidentified signaling pathway. In the current study, we
defined a new molecular subgroup of medulloblastoma characterized by
co-activation of the SHH and CXCR4 pathways. Numerous reports invol-
ving more than 20 cancer types have suggested that CXCR4 expression
has prognostic significance and that its activation can regulate cancer cell
migration, proliferation, and survival. Using in vitro as well as in vivo exper-
imental models, we demonstrated a critical functional interaction between
the SHH and CXCR4 pathways and report for the first time that both cell
surface localization and Galphai-induced signaling through CXCR4 can be
regulated by SHH activation. Human gene array analyses as well as geneti-
cally engineered mouse models of medulloblastoma indicated that the inter-
action between these pathways results in increased Cyclin D1 expression and
enhanced tumor growth. Finally, we showed that this mechanistic inter-
action renders SHH-driven medulloblastomas, including those with activat-
ing mutations of Smoothened, sensitive to CXCR4 antagonism in vivo.
Taken together, these data reveal a novel mechanism whereby the SHH
and CXCR4 pathways augment each other’s function, advance medulloblas-
toma molecular subgrouping, and mandate evaluating combined SHH and
CXCR4 antagonism in medulloblastoma where clinical trials with individual
SHH antagonists have been limited by resistance related to Smoothened
mutation.
CB-21. TARGETED DISRUPTION OF STAT3 SIGNALING
INHIBITS TUMOR GROWTH AND BRAIN METASTASES
BY CAVEOLIN-1 UPREGULATION
Wen-Tai Chu1, Hsueh-Te Lee1, Feng-Ju Huang2, Kenneth Aldape1, Jun Yao1,
Patricia S. Steeg3, Zhimin Lu1, Keping Xie1, and Suyun Huang1; 1University
of Texas MD Anderson Cancer Center, Houston, TX; 2Program in Cancer
Biology, The University of Texas Graduate School of Biomedical Sciences at
Houston, Houston, TX; 3Women’s Cancer Section, Laboratory of Molecular
Pharmacology, Center for Cancer Research, National Cancer Institute,
Bethesda, MD
Studies have demonstrated that Stat3 activation has a critical role in
tumorigenesis. However, the role and mechanisms of Stat3 activation in
brain metastases of breast cancer are unknown. In this study, we found
that activation of Stat3 and downregulation of caveolin-1, a novel down-
stream target of Stat3, are important for brain metastases. In human
tissues, there was increased expression of activated Stat3 but decreased
expression of caveolin-1 in brain metastases compared to that in primary
breast cancer, while increased expression of activated Stat3 correlated with
decreased caveolin-1 expression in brain metastases. Genetically engineered
overexpression of activated Stat3 suppressed caveolin-1 promoter activity
and gene expression, whereas both knockdown of Stat3 expression and
inhibition of Stat3 activation increased caveolin-1 promoter activity and
gene expression. Moreover, we have identified putative Stat3-binding
elements on caveolin-1 promoter and functionally verified a high affinity
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Stat3-binding site by EMSA, ChIP analyses, and promoter mutagenesis
assays. Furthermore, increased caveolin-1 expression by either caveolin-1
gene transfection or Stat3 knockdown attenuated breast cancer invasive
ability, while decreased caveolin-1 expression by either caveolin-1 knock-
down or Stat3 activation promoted breast cancer invasive ability. Finally,
by using stable SOCS-1-transfected 231-BR cells, we demonstrated that sup-
pression of Stat3 activation but upregulation of caveolin-1 inhibited tumor
growth and total abrogation of brain metastases of breast cancer in animal
models. Collectively, our findings provide both clinical and mechanistic evi-
dence that activated Stat3 directly binds to caveolin-1 promoter and inhib-
ited its transcription, hence contributing to breast cancer invasion and
brain metastases.
CB-22. BREVICAN, A PRO-INVASIVE MATRIX PROTEIN,
ACTIVATES PDGFR SIGNALING AND STIMULATES
OLIGODENDROCYTE PRECURSOR RECRUITMENT
IN THE GLIOMA MICROENVIRONMENT
Hosung Sim, Paula A. Agudelo-Garcia, Bin Hu, and Mariano S. Viapiano;
The Ohio State University, Columbus, OH
Malignant gliomas are virtually impossible to treat with conventional
therapies due to their chemoresistance and invasive ability. Glioma invasion
may be regulated in part by interactions with normal neural cells that would
facilitate tumor dispersion. Brevican is a brain-specific matrix protein
secreted by glioma cells and cleaved by ADAMTS metalloproteases in the
tumor matrix. This cleavage releases a 50-kDa fragment (“B50”) that pro-
motes glioma invasion through autocrine/paracrine EGFR activation. To
better understand the pro-invasive molecular mechanisms of B50, we gener-
ated U87MG glioma cells stably transfected with this bioactive fragment and
implanted them intracranially. B50-overexpressing tumors were larger than
controls and had invasive borders, as expected from the pro-invasive role
of B50. Interestingly, these tumors were surrounded by a large number of
NG2-positive and PDGFR-alpha-positive cells resembling oligodendrocyte
precursors (OPCs). Analysis of brevican and PGFDR expression in culture
showed that brevican mRNA matched the expression of PDGFR-alpha,
but not PDGFR-beta, in glioma cell lines and glioma stem cells. In addition,
U87MG and U251MG cells transfected with brevican or B50 showed elev-
ated levels of total and phosphorylated PDGFR-alpha. To investigate how
brevican could activate PDGFR, we tested its binding to PDGF. We observed
that B50 could bind to PDGFaa and protect the dimer from enzymatic degra-
dation. Finally, we analyzed the effect of purified brevican on Oli-Neu cells,
an Erb2-immortalized OPC line. We confirmed that brevican increased
PDGFR signaling in these cells as well as expression of the proliferative
gene Olig2. Together, these results suggest that brevican secreted by
glioma cells may activate PDGFR signaling both in the tumor and its micro-
environment, partly through PDGF stabilization. This signaling could recruit
nontumor cells, producing a favorable environment for glioma cell invasion
into the surrounding brain tissue. This finding highlights the importance of
interactions between glioma and tumor microenvironment for tumor
progression.
CB-23. FIBULIN-3 REGULATES NOTCH SIGNALING, TUMOR
INVASION, AND CELL SURVIVAL IN MALIGNANT GLIOMAS
Bin Hu, Paula A. Agudelo-Garcia, Joshua Saldivar, Hosung Sim,
Claire Dolan, Maria Mora, Gerard Nuovo, Susan Cole, and
Mariano S. Viapiano; The Ohio State University, Columbus, OH
Glioblastomas are the most common primary brain tumors and have
extremely poor prognosis owing to their highly invasive nature. Glioma
cells secrete a variety of ECM proteins that are absent in their glial counter-
parts and are critical molecules that favor invasion. We recently identified
fibulin-3 as an ECM protein highly expressed in gliomas but absent in
normal brain and rarely expressed in other solid tumors. We demonstrated
that fibulin-3 regulates the expression of metalloproteases and is sufficient
to promote tumor cell invasion through brain parenchyma. In the present
work, we describe a novel role of fibulin-3 regulating the sensitivity of
glioma cells to apoptotic treatments. Using gain- and loss-of-function
approaches, we observed that fibulin-3 overexpression reduced glioma cell
apoptosis in vitro and in vivo, while knockdown caused the opposite
effect. Because Notch signaling is a predominant prosurvival pathway in
gliomas and fibulin-3 bears homology with the Notch ligands of the Delta
family, we investigated a possible interaction of fibulin-3 with this
pathway. We observed that fibulin-3 induced Notch cleavage and activated
a Notch-dependent reporter in cultured glioma cells. Moreover, overexpres-
sion or knockdown of this protein regulated the expression of downstream
Notch effectors, such as Hes-1 and Hes-5, both in vitro and in vivo.
Furthermore, analysis of fibulin-3 and Hes-1 in clinical samples showed a
strong correlation between expression of both proteins and tumor grade.
Finally, we demonstrated that the pro-invasive effect of fibulin-3 can be
abolished by blockade of Notch signaling using pharmacological inhibitors
or Notch1 siRNA. In summary, our results reveal a potentially novel
mechanism by which a tumor-associated matrix molecule can activate
Notch signaling and modulate this major protumor pathway in gliomas.
These results highlight fibulin-3 as a tumor-specific, highly-accessible
target with therapeutic potential.
CB-24. POLYVALENT GOLD NANOPARTICLES
FUNCTIONALIZED WITH RNAI AS ANTIGLIOMA
THERAPEUTICS
Alexander H. Stegh; Northwestern University, Chicago, IL
Glioblastoma (GBM) is a lethal brain tumor characterized by intense
resistance to extant chemotherapy, radiation, and targeted therapies.
Bcl2L12 (for Bcl2-Like 12) is a cytoplasmic and nuclear glioma oncoprotein
that is overexpressed in greater than 90% of primary GBM and confers
resistance toward therapy-induced apoptosis. On the molecular level,
Bcl2L12 binds and inhibits caspase-7 and blocks caspase-3 maturation
through upregulation of the small heat-shock protein and caspase-3-specific
inhibitor alpha-B-crystallin. In addition, nuclear Bcl2L12 physically interacts
with the p53 tumor suppressor and robustly represses p53 transactivation
activities. To therapeutically suppress Bcl2L12’s diverse and potent glioma-
genic activities, we employed a gene silencing approach using small interfer-
ing RNA (siRNA)-conjugated polyvalent gold nanoparticles (RNA-Au-NPs)
to knockdown and inactivate Bcl2L12 signaling in glial cells. Our studies
document that RNA-Au-NPs exhibit superior biological stability, highly sig-
nificant knockdown efficacies, robust cellular uptake, biocompatible intratu-
moral delivery upon systemic i.v. and local administration, reduced
off-target effects, and diminished activation of innate immune responses
compared to conventional lipoplex-delivered RNAi. In particular, we
could show that RNA-Au-NPs are single entity agents, which are 500
times more effective in knocking down Bcl2L12 than conventional
RNAi-based methods and do not require auxiliary transfection agents.
MRI studies using Gd(III)-conjugated RNA-Au-NPs confirmed that these
nanomaterials penetrate intracranial brain tumors highly effectively
without the need for convection-based enhanced delivery. Finally,
RNA-Au-NPs exhibited highly effective uptake into various primary and
transformed glial cell lineages, in particular glioma stem cells, and provoked
robust and persistent knockdown of Bcl2L12, which resulted in sensitization
of cells toward apoptosis. Thus, silencing Bcl2L12 signaling by nano-RNAi
represents a novel therapeutic approach to restrain GBM pathogenesis.
CB-26. S100A8/A9 PLAY AN IMPORTANT ROLE IN
ENDOGENOUS ONCOGENIC KRAS-MEDIATED ASTROGLIOSIS
Myung-Jeom Ryu, Yangang Liu, Juan Du, Xiaofen Zhong, Shruti Marwaha,
Hongda Li, Jingyong Wang, Shahriar Salamat, Qiang Chang, and
Jing Zhang; University of Wisconsin-Madison, Madison, WI
Previous studies suggest that upregulation of Ras signaling in neurons
promotes astrocytoma formation in a cell nonautonomous manner.
However, the underlying mechanisms remain unknown. We hypothesized
that these genetically altered neurons secret growth factors that promote
astrocyte proliferation and/or survival. To test our hypothesis, we gener-
ated compound mice (LSL Kras G12D/ + ; CamKII-Cre) that express
endogenous oncogenic Kras in postmitotic neurons since P1. These mice
developed progressive astrogliosis, which is associated with hyperactiva-
tion of Ras signaling pathways. Microarray analysis using control and
mutant cortexes identified that both S100A8 and S100A9 are significantly
overexpressed in the mutant cortex. We further validated this microarray
result using semiquantitative RT-PCR and western blot analysis. S100A8
and A9 are chemokines predominantly expressed in myeloid cells (e.g.,
neutrophils and macrophages) and have been implicated in promoting
tumor cell growth and metastasis through their expression in the stromal
myeloid cells. However, our preliminary results indicate that overexpres-
sion of S100A8 and A9 in the mutant cortex is not due to increased micro-
glias or contaminated circulating myeloid cells in our cortex protein
extractions. Rather, the mutant neurons and their surrounded astrocytes
overexpress these proteins. Consistent with this observation, we found
that astrocytes express both TLR4 and RAGE, receptors for S100A8/
A9. Moreover, purified S100A8/A9 heterodimer but not S100A8 or
S100A9 alone promotes growth of primary astrocytes in vitro. In
summary, our results reveal a novel role of S100A8/A9 in endogenous
oncogenic Kras-associated astrogliosis.
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CB-27. MOLECULAR AND FUNCTIONAL
CHARACTERIZATION OF MIR-137 IN OLIGODENDROGLIAL
TUMORS
Ho-Keung Ng1, Ling Yang1, Wai Sang Poon1, Liangfu Zhou2, and Jesse
C. Pang1; 1The Chinese University of Hong Kong, Hong Kong, Hong Kong;
2Fudan University, Shanghai, China
MicroRNAs are short noncoding RNAs that function as key regulators of
diverse cellular processes through negative control on gene expression at the
posttranscriptional level. A recent study reported (Silber et al., BMC Med
2008;6:14) that miR-137 expression was diminished in anaplastic astrocyto-
mas and glioblastomas. The aims of this study were to investigate whether
miR-137 was involved in oligodendroglial tumors and to elucidate the bio-
logical functions of miR-137 in gliomagenesis. Quantitative RT-PCR analy-
sis revealed that miR-137 was significantly downregulated in 17 of 20 (85%)
oligodendrogliomas and 16 of 16 (100%) oligoastrocytomas examined com-
pared to normal brain tissues (p , 0.05). Ectopic expression of miR-137
inhibited cellular proliferation and induced apoptosis in oligodendroglioma
and glioblastoma cells. To identify miR-137 targets, a computational
approach was employed for target prediction. One of the candidate genes,
CSE1L (chromosome segregation 1-like), was found to be downregulated
at the protein but not at the mRNA level upon forced miR-137 overexpres-
sion. Luciferase reporter assay showed that miR-137 could interact with the
putative miR-137 binding site in the 3’ untranslated region of CSE1L but not
with a mutated miR-137 binding site. These results strongly suggest that
CSE1L is a target of miR-137. Immunohistochemical analysis further
demonstrated that CSE1L was overexpressed in oligodendroglial tumors.
Moreover, knockdown of CSE1L by RNA interference led to reduced pro-
liferation and induced apoptosis in glioma cells. These effects were similar
to those observed after miR-137 overexpression, but to a lesser extent,
suggesting that miR-137 may mediate its effects partly through CSE1L.
CSE1L has been implicated in cellular proliferation and apoptosis and is
involved in modulating expression of a subset of p53 target genes. In con-
clusion, our results demonstrate that miR-137 deregulation is common in oli-
godendroglial tumors and suggest that the miR-137/CSE1L axis may serve
as a potential therapeutic target for treatment of oligodendroglial tumors.
CB-28. THE SMALL GTPASE RHOG MEDIATES THE
INVASIVENESS AND SURVIVAL PROPERTIES OF
GLIOBLASTOMA CELLS
Amanda Chan1, Sebastien Didier1, Aneta Kwiatkowska1, Matt Ennis2,
Shannon Fortin2, Elisabeth Rushing3, Jennifer Eschbacher4, Nhan Tran2,
and Marc Symons1; 1The Feinstein Institute for Medical Research,
Manhasset, NY; 2Translational Genomics Research Institute, Phoenix, AZ;
3UniversitätsSpital Zürich, Zurich, Switzerland; 4Barrow Neurological
Institute, Phoenix, AZ
The invasion of glioblastoma cells into regions of the normal brain is a
critical factor that limits current therapies for malignant astrocytoma. We
examined the role of RhoG in the invasive behavior of glioblastoma cells.
We found that siRNA-mediated depletion of RhoG strongly inhibits invasion
of glioblastoma cells through brain slices ex vivo. In addition, depletion of
RhoG strongly decreases colony formation, demonstrating a role for RhoG
in glioblastoma cell survival. Importantly, we found that RhoG is activated
by HGF and EGF, 2 factors that are clinically relevant drivers of glioblas-
toma malignant behavior. In addition, depletion of RhoG strongly inhibits
activation of the Rac1 GTPase by both HGF and EGF. We also observed
that in addition to controlling cell invasion, RhoG regulates glioblastoma
cell migration and the formation of lamellipodia and invadopodia, all
of which are functions that have been shown to be Rac1-dependent.
However, unlike Rac1, depletion of RhoG does not significantly inhibit
cell proliferation, suggesting that RhoG regulates a subset of
Rac1-controlled functions. Importantly, in contrast to Rac1, the functions
of RhoG in normal cells appear to be rather restricted, and RhoG knockout
mice display no significant phenotypes. Thus, our results suggest that target-
ing RhoG-mediated signaling presents a novel avenue to limit the malignant
behavior of glioblastoma tumors.
CB-29. MOLECULAR BASES OF RESISTANCE TO TARGET
THERAPIES IN PATIENTS WITH PRIMARY AND RECURRENT
MENINGIOMA
Gloria Roldan, John B. McIntyre, Jacob Easaw, and Anthony Magliocco;
Tom Baker Cancer Centre, Calgary, AB, Canada
INTRODUCTION: Meningiomas are common primary brain tumors that
are initially treated by surgical resection. However, atypical and anaplastic
meningiomas have a higher risk of recurrence. Frequently, multiple
recurrences become progressively more challenging to manage. To date, sys-
temic therapies have proven mostly ineffective. We assessed if a rationale
exists for the treatment of meningiomas with therapies targeting molecular
biomarkers. METHODS: Eight adult patients (3 women) with pathological
diagnosis of atypical meningioma treated at the Tom Baker Cancer Center,
Calgary, Canada, were included. They had signed informed consent and
tissue was available from the initial surgery and at least one additional resec-
tion (median, 3 surgeries; range, 2 to 6). We investigated EGFR tyrosine
kinase mutations (L858R; exon 19 deletions), EGFRvIII expression,
MGMT promoter methylation status, expression of the telomerase catalytic
subunit hTERT, and mutational status of the IDH1 gene. RESULTS: There
was no change in biomarker status from the initial surgical specimens
through subsequent resections with respect to EGFR, hTERT, and IDH1.
No patients harbored EGFR or IDH1 mutations. No patient expressed the
telomerase subunit hTERT. The MGMT promoter was found to be
unmethylated in all specimens except for one patient with multiple
radiation-induced meningiomas (MGMT promoter was methylated in one
of them in 2 resections without clinical evidence of response to temozolo-
mide). CONCLUSIONS: These results suggest that EGFR tyrosine kinase
mutations and the EGFRvIII deletion mutant are not manifested in menin-
giomas. Previous reports have shown hTERT to be present in atypical menin-
giomas; however, we were unable to detect any hTERT expression in our
cohort. Mutations in the IDH1 gene were not observed in our study.
Lastly, MGMT promoter methylation was found to be predominantly
unmethylated. Our results suggest that primary and recurrent meningiomas
do not express the target for molecular therapies that illicit beneficial
response in other tumor types.
CB-30. MOLECULAR MECHANISMS OF ACQUIRED
RESISTANCE TO EGFR TYROSINE KINASE INHIBITORS
IN GBM
Jill Wykosky, Webster Cavenee, and Frank Furnari; Ludwig Institute for
Cancer Research, La Jolla, CA
EGFR-targeted therapies such as the tyrosine kinase inhibitors (TKIs) gefi-
tinib and erlotinib have had limited success clinically in GBM. However,
some of the most common mechanisms of resistance to these agents in
other solid tumors are rarely present in GBM. In an effort to identify molecu-
lar mechanisms of acquired resistance to EGFR TKIs in GBM, we utilized
ink4a/arf 2/2 astrocytes overexpressing delta-EGFR and having wild-type
or deleted PTEN. To model TKI-resistance in vitro, cells were seeded in soft
agar with 1 mM gefitinib or erlotinib for 2 weeks; during this time the growth
of colonies was inhibited. The dose was escalated to 2 mM, and after 3 weeks
TKI-resistant colonies began to form and were isolated to form clonal cell
lines. In 3 PTEN wild-type TKI-resistant lines, delta-EGFR expression was
not decreased, and gefitinib inhibited receptor phosphorylation in a
manner identical to that observed in parental cells. Interestingly, 2 of these
3 cell lines demonstrated decreased PTEN expression and increased AKT
phosphorylation. Removal from the maintenance dose of TKI resulted in res-
toration of delta-EGFR and ERK phosphorylation to a level several-fold
greater than that in parental cells. Notably, the TKI-resistant phenotype
was reversible, and these cells became more sensitive to gefitinib and erloti-
nib than pretreatment parental cells. Overall, we have generated and charac-
terized a model system for the identification of mechanisms of resistance to
EGFR TKIs in GBM. We have identified at least 2 different resistance scen-
arios in cells with wild-type PTEN: decrease in PTEN expression, and
another as-of-yet unknown mechanism that does not appear to involve
PI3K. The reversibility of resistance and subsequent increased sensitivity to
TKIs have potential clinical implications. This work forms the basis for
our effort to uncover novel targets or approaches to therapy that may
increase the utility of these drugs for treatment of GBM.
CB-31. MGMT PROMOTER METHYLATION AND DNA
MISMATCH REPAIR IN PRIMARY AND RELAPSED
GLIOBLASTOMA
Dan Lu1, Ellein Mreich1, Sylvia Chung1, Charlie Teo2, Helen Wheeler3, and
Kerrie L. McDonald1; 1Prince of Wales Clinical School, University of New
South Wales, Sydney, Australia; 2Centre for Minimally Invasive
Neurosurgery, Prince of Wales Private Hospital, Sydney, Australia;
3Northern Cancer Institute, North Shore Private Hospital, Sydney, Australia
Conventional treatments for newly diagnosed glioblastoma (GBM)
include maximal surgical resection and radiotherapy with concomitant and
adjuvant temozolomide (TMZ). However, nearly all patients inevitably
experience tumor recurrence during or after the chemotherapy phase, and
the relapsed lesion is typically refractory to further treatment. Both O6
methylguanine methyltransferase (MGMT) and mismatch repair pathway
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(MMR) are involved in DNA repair. We have examined the incidence of
MGMT methylation, assessed by pyrosequencing, in a retrospective cohort
of 140 GBM specimens. An estimated 29% of patients were positive for
MGMT methylation. While MGMT methylation did not associate with an
overall survival advantage in our cohort, progression-free survival was sig-
nificantly prolonged. Interestingly, we also identified a proportion (36%)
of unmethylated patients who showed a strong survival benefit of over 18
months on average. In our preliminary in vitro studies, using a panel of 8
commercially available GBM cell lines, reduced protein levels of MSH6
and MLH1 specific to the recurrent GBM cell line DBTRG-05MG were
observed, but not in any of the primary cell lines. We sequenced 5 regions
of MSH6 genome, covering 6 mutation hot spots, as previously reported
[1], in all 8 cell lines and DNA extracted from 15 recurrent GBM clinical
specimens. All 5 regions appeared very well conserved, and no mutations
were identified. To determine relative sensitivity to treatment, we treated
the cell lines with TMZ and radiation therapy (6 Gy). DBTRG-05MG
showed a slightly increased resistance to TMZ but not to combined TMZ/
radiation or radiation alone. These results indicate that other mechanisms
are involved in mediating resistance to treatment. Analyses are underway
to decipher the protein expression levels of MMR in relapsed clinical
specimens and to look for novel mechanisms associated with this acquired
resistance. [1]Yip S et al., Clin Cancer Res 15(14), 4622-4629, 2009
CB-32. NEUROTROPHIN RECEPTOR SIGNALING IN GLIOMA
Samuel Lawn and Peter Forsyth; University of Calgary, Calgary, AB, Canada
Glioblastoma multiforme (GBM) is a highly invasive disease that is refrac-
tory to current treatments. Previous work by this lab has identified and
characterized the role of the neurotrophin receptor p75NTR in promoting
neurotrophin-dependent glioma cell invasion. Neurotrophins are a group
of growth factors that signal through the p75NTR receptor (TNFR family)
and Trk receptors (receptor tyrosine kinases) to regulate diverse functions
such as neuronal survival and cell motility. Here, we have further investi-
gated the role of p75NTR and Trk receptors in mediating the response of
patient-derived gliomasphere cultures (commonly referred to as brain
tumor initiating cells [BTICs]) to neurotrophins. BTIC cultures express a
diverse repertoire of neurotrophin receptors, and the expression of specific
Trk receptors (TrkA, TrkB, and TrkC) correlates with the response of each
cell line to specific neurotrophin ligands (NGF, BDNF, and NT3). In particu-
lar, BDNF and NT3 promote the growth of BTICs and stimulate MAPK
pathway activity. Perturbation of Trk receptor function by pharmacological
inhibition or by lentiviral-mediated shRNA knockdown renders BTICs
unresponsive to neurotrophins in terms of growth promotion and MAPK
stimulation. The contribution of p75NTR to these phenotypes is being inves-
tigated by utilizing shRNA and by FACs fractioning of BTIC cultures into
populations positive and negative for p75NTR expression. The in vivo
relevance of these observations is being examined through orthotopic injec-
tion of neurotrophin receptor knockdown BTICs and by treatment of
gliomas with Trk receptor inhibitors, which are currently in clinical trials
for a variety of hematological and solid tumors.
CB-33. DECRYPTING CHROMOSOME 10Q DELETION
IN GLIOBLASTOMA: AN INTERSPECIES COMPARISON
OF GENE COPY NUMBER ALTERATIONS
Adam M. Sonabend, Liang Lei, Benjamin Kennedy, Craig Soderquist,
Paolo Guarnieri, Richard Leung, Jonathan Yun, Julia Sisti, Mike Castelli,
Samuel Bruce, Rachel Bruce, Thomas Ludwig, Steven Rosenfeld, Jeffrey
N. Bruce, and Peter Canoll; Columbia University, New York, NY
Human glioblastomas (GBM) acquire genetic deletions that are considered
critical for tumor development, presumably because these deletions result in
the loss of critical tumor suppressor genes. The distinction between these
functionally relevant genes and bystanders within the same loci is difficult
since oftentimes a single deletion includes many genes. Chromosome 10q
deletion, the most common found in GBM, includes the tumor-suppressor
gene PTEN, which is well known to play an important role in development
of GBM. However, several groups have proposed that the loss of other
tumor-suppressor genes, in addition to PTEN, may also contribute to the
functional significance of chromosome 10q deletion in GBM. To explore
this possibility, we performed comparative genomic hybridization of a
retrovirus-induced mouse model of GBM in which PTEN was experimen-
tally deleted by Cre-recombinase, in combination with PDGF overexpres-
sion, as tumor initiating alterations. The resulting mouse tumors
consistently developed a series of deletions that included several genes that
map to human chromosome 10q and are found among the most common
genetic deletions seen in human GBM. Interestingly, these genes are found
in multiple independent deletions localized in 3 different mouse
chromosomes, suggesting that there is independent selective pressure for del-
etion of these different genetic loci. Furthermore, the mouse tumors did not
suffer frequent copy number alterations within the chromosomal region that
contains PTEN, consistent with the fact that this gene was experimentally
inactivated by Cre-mediated deletion during tumor induction. These
results identify multiple distinct genetic deletions, in addition to PTEN,
that provide independent selective advantage during the development of
GBM. Cross-species comparisons between human GBM and murine
glioma models constitute a valuable approach for refining lists of candidate
genes that play a role in the evolution of GBM.
CB-34. ISOGENIC GLIOBLASTOMA STEM CELL LINES WITH
DIFFERENT EGFR AMPLIFICATION LEVELS ESTABLISHED
FROM INDIVIDUAL TUMORS
Katrin Lamszus1, Alexander Schulte1, Hauke S. Günther1, Sabine Riethdorf
1, Heidi S. Phillips2, and Manfred Westphal1; 1University Medical Center
Hamburg-Eppendorf, Hamburg, Germany; 2Genentech, Inc., South
San Francisco, CA
INTRODUCTION: EGFR amplification is present in almost 50% of all
glioblastomas (GBM) and is frequently associated with expression of a trun-
cated, constitutively active variant, EGFRvIII. Experimental limitations to
study these alterations exist as both are rapidly lost when GBMs are taken
into culture. We developed conditions facilitating the growth of cell lines
that either maintain high-level EGFR amplification/EGFRvIII expression
or not, allowing direct comparison between cells with a heterogeneous
EGFR status derived from the same original tumor. METHODS: Fresh
tumor material was cultured using glioma stem cell conditions with modifi-
cations. The resulting matched pairs of cell lines and original tumors were
analyzed by RT-PCR, western blot, FACS, and FISH for different levels of
EGFR gene amplification, EGFRvIII expression, EGFR/EGFRvIII protein,
and in vivo tumorigenicity. RESULTS: From 5 freshly resected GBM, 2-3
primary cultures were generated that differed in EGFR gene amplification
levels, expression of EGFRvIII, and levels of EGFR/EGFRvIII protein,
depending on culture conditions. Cultures from 2 GBM developed into
pairs of permanent cell lines. The first pair consisted of one cell line with
high-level EGFR amplification and high EGFR protein expression, whereas
its isogenic sister-line lacked EGFR amplification. The second pair comprised
one line showing EGFRvIII expression, EGFR amplification and high
EGFRvIII/EGFR protein levels, whereas these alterations were absent in
the sister-line. Nude mice injected with EGFR-amplified cell lines died
significantly earlier than those xenografted with nonamplified lines, and
the EGFR/EGFRvIII status was maintained in vivo. Analysis of xenograft
tumors showed that they recapitulated the phenotype of the cell lines and
resembled their parental primary tumors on protein and genomic levels.
CONCLUSION: Our cell lines provide a model to study the function of
EGFR amplification/EGFRvIII expression in glioma cells and assess the
impact of intratumoral EGFR status heterogeneity on the response to
EGFR-targeting and other agents.
CB-35. KRAS IS THE TARGET GENE OF 41 OF 53 MICRORNA
CLUSTERS IN CHROMOSOME 14Q32.31
Tali Siegal, Daniel Zrihan, Avital Granit, and Iris Lavon; Gaffin Center for
Neuro-Oncology, Hadassah Hebrew University Medical Center, Jerusalem,
Israel
BACKGROUND: We previously demonstrated that underexpression of a
cluster of 53 microRNAs (miRNAs) on chromosome 14q32.31 is consist-
ently present in gliomas. Our presumption was that this region operates as
a tumor suppressor and that dysregulation of the related miRNAs may
lead to subsequent abnormal expression of their targets, resulting in tumor-
igenesis. AIM: To identify the target genes of the miRNAs from the 14q32.31
region and their related oncogenic function. METHODS: Four bioinformatic
algorithms (PITA, TargetScan, PicTar, and miRanda) were used to identify
the potential target genes of miRNAs from this cluster. A reporter plasmid
harboring the 3′-UTR region of putative target genes downstream of the luci-
ferase coding region were constructed. To study the role of the target genes
on tumorigenesis, mir-323-3p, mir-369-3p, and mir-433 from this region
were introduced into mouse and human glioma cell lines, and their effects
on proliferation and migration were evaluated. RESULTS: Among the puta-
tive identified candidates, KRAS was selected for further analysis because
77.4% of the miRNAs from this cluster were predicted to target this onco-
gene. A 70%-80% reduction in luciferase activity was noted following
cotransfection of KRAS 3-UTR reporter plasmid with each of the individual
pre-miRNAs 323-3p, 369-3p, 433, and 90% for all of them together. Minor
overexpression (.10 fold) of miRNAs 323-3p and 369-3p significantly
reduced the proliferation and migration rate of both glioma cell lines.
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CONCLUSIONS: Our study indicates that miRNA-cluster in chromosome
14q32.31 may function as a tumor suppressor gene through various mechan-
isms including inhibition of tumor cell growth and migration. It also suggests
that this miRNA-cluster exerts its tumor suppression effect through post-
transcriptional regulation of KRAS based on the account that all miRNA
from this region are underexpressed in gliomas, while 77.4% of them puta-
tively target the KRAS oncogene, and the findings that the 3 tested miRNA
reduced luciferase activity following cotransfection with KRAS 3-UTR,
CB-36. DUAL INHIBITION OF HDACS AND KDM1A LEADS
TO THE EXPRESSION OF GENES INVOLVED IN APOPTOSIS
Melissa Singh and Joya Chandra; The University of Texas MD Anderson
Cancer Center, Houston, TX
Glioblastoma multiforme (GBM) is a particularly aggressive brain tumor
and, despite innovative therapies, remains a clinically devastating disease.
Enzymes that control epigenetic alterations are popular targets for cancer
therapy owing to the dynamic nature of these modifications and their
ability to control cellular processes that lead to oncogenesis. Histone deace-
tylases (HDACs) are one family of enzymes that have been targeted for
cancer therapy; however, HDAC inhibitors (HDACi) show only moderate
success in GBM. Our previous studies evaluated the cellular consequences
of simultaneously inhibiting HDACs and the lysine specific demethylase 1
(KDM1A), another enzyme that regulates epigenetic marks. We found that
simultaneously inhibiting these enzymes increased cell death in GBM cells
but not their normal counterparts. Since HDAC1/2 and KDM1A are
found in similar complexes that function to regulate transcription, we
hypothesized that these 2 enzymes cooperate to enhance cell death by con-
trolling the expression of genes that play a role in apoptosis. Using a
focused qRT-PCR array, we evaluated the expression profiles of 84 genes
involved in apoptosis in GBM cells transfected with control or
KDM1A-specific shRNA and left untreated or treated with the HDACi vor-
inostat. Our results reveal several genes that are altered upon treatment with
vorinostat, some of which are further changed when both HDACs and
KDM1A are inhibited. Surprisingly, mRNA expression of both p53 and
p73 is reduced by 50% in KDM1A knockdown cells and further reduced
(.90%) upon treatment with vorinostat for 24 hours. Similar to mRNA
expression, p53 protein is also decreased in KDM1A knockdown cells and
almost undetectable with the addition of vorinostat. Further studies evaluat-
ing the molecular mechanism by which HDACs and KDM1A regulate p53
will provide molecular insight into the mechanism by which these epigenetic
modifiers interact to control cell survival and may suggest novel options for
GBM therapy.
CB-37. ENDOGENOUS DOWNREGULATION EFFECT OF DRUG
RESISTANCE GENE MGMT BY MICRORNA
Daisuke Ogawa, Hiroshi Nakashima, Jakub Godlewski, and Antonio
E. Chiocca; The Ohio State of University, Columbus, OH
INTRODUCTION: The drug resistance gene O6-methylguanine-DNA
methyltransferase (MGMT) is thought to represent a mechanism of glioma
resistance, counteracting TMZ treatment and possibly worsening patient
prognosis. MicroRNAs are 22-nucleotide small RNAs that regulate trans-
lation and decay of their target mRNAs. OBJECTIVE: In this study, we
searched for microRNAs that suppress translation of MGMT. METHODS
AND FINDINGS: Based on our in silico analysis, we picked up 6
microRNAs that putatively target MGMT. Two of 6 selected microRNAs
downregulated MGMT mRNA by more than 40% in the T98G glioma
cell line that is usually resistant to TMZ. This led to downregulation of
MGMT protein, assayed by western blot. MicroRNA-transfected T98G
cells showed increased sensitivity to TMZ, similar to the sensitivity
of U87MG cells that are very sensitive to TMZ. CONCLUSIONS:
Suppression of the drug-resistance gene MGMT to increase chemosensitivity
to TMZ can be achieved with microRNAs.
CB-38. IDENTIFICATION OF EGFRVIII-INDUCED GENE
SIGNATURES USING RAT GLIOMA MODEL AND HUMAN
GBMS
Gurpreet S. Kapoor, Harish Poptani, Ranjit Ittyerah, and Donald
M. O’Rourke; University of Pennsylvania, Philadelphia, PA
EGFRvIII, a constitutively active truncated mutant of epidermal growth
factor receptor (EGFR) has been shown to increase neoplastic transform-
ation and tumorigenicity in a variety of tumors including GBMs.
However, transcriptional mediators of EGFRvIII have not been fully eluci-
dated. In the present study, we analyzed 52 primary human GBMs and a
9L.EGFRvIII rat brain tumor model to identify EGFRvIII-specific gene signa-
tures. EGFRvIII-expressing 9L gliosarcoma cells exhibited increased trans-
formation and invasion when compared to empty vector (EV) controls.
MRI imaging of Fischer rats either bearing 9L.EV or 9L.EGFRvIII intracra-
nial tumors revealed significantly enhanced tumor volume in EGFRvIII
tumors. Immunohistochemical analyses showed increased phosphorylation
of Akt, Erk1/2, PLC-g, Gab1, and SHP-2 in EGFRvIII-bearing tumors.
Gene expression analyses of 9L.EGFRvIII tumors demonstrated increased
expression of 1498 gene probes when compared to control tumors
(p ¼ 0.05). David enrichment analyses revealed 9 clusters of genes that
mediate increased transformation, invasion, glycolysis, and hypoxia in
9L.EGFRvIII tumors. Comparative evaluation of gene expression profiles
from rat tumors and primary human GBMs revealed 9 novel genes (ckap4,
lrp5, fat3, slc7a1, cdk6, socs2, aqp1, spry2, and aebp1) that were signifi-
cantly upregulated in EGFRvIII-expressing tumors. In the present study,
we validated physiological significance of spry2 and aebp1 using
RNAi-mediated gene silencing and immunoprecipitation assays and demon-
strated that Spry2 and AEBP1 physically bind to EGFRvIII to inhibit its
transforming efficiency. Collectively, our data presents a comprehensive
EGFRvIII-specific gene signature profile using a rat glioma model and
human GBMs and characterizes potential targets to inhibit EGFRvIII-
mediated transforming phenotypes in malignant gliomas.
CB-39. NUCLEAR FIP200 AND RB EXPRESSION IN BRAIN
METASTASIS FROM BREAST CANCER: POTENTIAL
PREDICTORS OF SURVIVAL
Nooshin Hashemi Sadraei, Monica Burgett, Manmeet Ahluwalia,
Russell Tipps, Divya Khosla, Robert Weil, Amy Nowacki, Richard Prayson,
Ting Shi, and Candece Gladson; Cleveland Clinic Foundation,
Cleveland, OH
Patients with brain metastasis from breast cancer have a poor outcome
with significant variation in overall survival (OS). No marker to predict sur-
vival exists. FIP200 is a signaling node; in the nucleus, it inhibits cell prolifer-
ation by promoting Rb1 and p21 transcription, and in the cytoplasm it
promotes cell survival by inhibiting Pyk2 activation and positively regulating
autophagy. FIP200 cellular localization and genetic alterations have not been
examined in brain metastasis from any cancer. In a retrospective analysis,
brain tissues of 21 patients with brain metastasis from invasive ductal
breast cancer obtained between 8/2000 and 3/2010 and randomly chosen
based on availability of tissue were evaluated for FIP200 and Rb expression
and localization by immunohistochemistry, along with 15 primary breast
cancer samples. Genetic alterations were evaluated by DNA array analysis.
Low levels of expression of nuclear Rb1 (,30%) and nuclear FIP200
(,20%) were seen in 11 and 13 of 21 patients with brain metastasis, respect-
ively, and there was a trend towards shorter median OS in these patients as
compared to patients with ≥ 30% nuclear Rb and ≥ 20% nuclear FIP200.
The pattern of FIP200 in 15 primary breast cancers was very different; no
nuclear FIP200 was detected. Previously other investigators reported
FIP200 deletion or mutation in 20% of primary breast cancers. On DNA
analysis for copy number variation and LOH in the brain metastases, we
found loss of p53 in 4 of 11 patients, ErbB2(Her-2) amplification in 4 of
11, no deletion/mutation in Rb1, and no deletion in FIP200. The pattern
of nuclear expression of Rb1 and FIP200 in breast cancer metastasis to the
brain is different in patients with a longer OS. An expanded study is
underway to determine whether FIP200 and/or Rb1 nuclear expression is
predictive of OS in these patients and whether their expression is linked.
CB-40. PREDICTION OF THERAPY RESPONSE IN SHORT-TERM
TREATED PRIMARY TUMOR-INITIATING CELLS IN VITRO
Sylvia Moeckel, Katharina Meyer, Anja Bosserhoff, Rainer Spang,
Petra Leukel, Arabel Vollmann, Birgit Jachnick, Christina Stangl,
Martin Proescholdt, Ulrich Bogdahn, and Peter Hau; University of
Regensburg, Regensburg, Germany
The increasing knowledge of the pathogenesis of tumor formation and
progression in high-grade gliomas has led to the development of a novel
group of therapeutic agents that includes small molecule kinase inhibitors.
These novel agents often directly interfere with growth factor signaling path-
ways that are upregulated in brain tumors and are supposed to interfere with
oncogenesis. Despite promising preclinical studies, results of pilot trials have
been generally disappointing. One reason may be the enormous molecular
and genetic heterogeneity between individual tumors. Therefore, it is
demanding to correlate individual response to the general susceptibility of
a certain tumor entity to certain substances. In our preclinical study, we
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examined the effect of the receptor-tyrosine-kinase (RTK) inhibitor Sunitinib
in 20 tumor-initiating cell lines using the following approach: culture under
serum-free conditions; short-term culture and treatment; and hypothesis-free
evaluation of a response signature by microarray. In parallel signaling path-
ways were evaluated by western blot and response was evaluated by func-
tional assays. Cells were treated with Sunitinib or DMSO (control) alone
or together with VEGF-A/PDGF-AB for 6 hours. The phosphorylation of
signaling molecules downstream of these RTKs was assessed by western
blots. The results reveal that stimulation as well as inhibition of particular
RTKs has different downstream effects in distinct cell lines. We are on our
way to further correlate this data to the expression profiles obtained from
microarrays and the outcome of functional assays to define a molecular sig-
nature that can predict treatment response in vitro. So far our data clearly
demonstrate the heterogeneity of treatment response on a molecular level
and underlines the importance to preselect patients for clinical trials. We
mandate that the concept of a personalized treatment requires an in vitro
drug testing tool that enables the prediction of therapy response within a
single short-term assay.
CB-41. DIFFERENTIAL EXPRESSION OF G PROTEIN-COUPLED
RECEPTOR KINASES IN GLIOBLASTOMA MULTIFORME
Gurvinder Kaur, Matthew Sun, Rajwant Kaur, Orin Bloch, Brian Jian, and
Andrew T. Parsa; UCSF, San Francisco, CA
G protein-coupled receptor kinases (GRKs) comprise a family of 7 trans-
membrane serine/threonine protein kinases that regulate signal transduction
by phosphorylating activated G protein-coupled receptors, leading to their
desensitization, endocytosis, intracellular trafficking, and resensitization.
Recent studies have highlighted differential expressions of GRKs in breast,
ovarian, and thyroid cancers, suggesting their potential role in tumorigenesis
and tumor growth. Furthermore, GPCRs, including EGFR, PDFGR, and
VEGF-R, are well known for roles in regulating GBM proliferation and intra-
tumoral angiogenesis. Therefore, it is crucial to investigate the role of GRKs
in GBM. To analyze the expression of GRKs in GBM, we established 20
glioma stem cell lines in serum-free condition along with more differentiated
GBM cell lines grown in the presence of serum from 20 freshly collected
GBM specimens. We compared GRKs protein and mRNA expression
levels in 2 types of cell lines. We found that GBM-derived glioma cells
have higher expression of GRK3. On the other hand, more differentiated
tumor-derived cells have higher levels of GRK2 and GRK6. However,
GRK5 was expressed equally in both types of tumor cell lines. In contrast,
normal human astrocytes expressed relatively equal but lower levels of
GRK2, 3, 5, and 6. To further evaluate the functional role of GRKs in
GBM clinically, we utilized the TCGA database, and the resulting
Kaplan-Meier survival analysis demonstrated that GRK5 downregulation,
compared to its upregulation in GBM, correlated with significantly
reduced overall survival (p , 0.0001). For the remaining GRKs (GRK2,
GRK3 and GRK6), there were no data available on TCGA to assess their sig-
nificance in GBM. These findings suggest that altered GRK protein
expression in GBM could be involved in the pathogenesis and proliferation
of this malignant tumor.
CB-42. TUMOR-ASSOCIATED MESENCHYMAL STROMAL
CELLS INCREASE PROLIFERATION AND MAINTAIN
STEMNESS OF GLIOMA STEM CELLS THROUGH THE IL6/
STAT3 PATHWAY
Anwar Hossain, Naoki Shinojima, Joy Gumin, Gao Feng, and Frederick
F. Lang; The University of Texas MD Anderson Cancer Center, Houston,
TX
Though there has been considerable progress in the understanding of the
genetics and biology of glioblastoma multiforme (GBM), little is known
about the tumor microenvironment. Mesenchymal stromal cells (MSC) are
components of the tumor microenvironment in many cancers, including
GBM. To explore the role of MSCs, we isolated tumor-associated mesench-
ymal stromal cells (TA-MSC) from GBM specimens using established
markers (CD73 + /90 + /105+). We also isolated glioma stem cells
(GSC) based on marker expression and sphere formation. To identify the
effect of TA-MSCs on GSCs, we cocultured them in transwell plates. GSC
coculture with bone marrow-derived MSCs served as a positive control
and coculture with human brain-derived microvascular endothelial cells
(HBMEC) served as a negative control. GSCs cocultured with TA-MSCs
had increased proliferation and self-renewal compared with GSCs cocultured
with HBMECs or in NSC media alone. GSCs that had been cocultured with
TA-MSCs were implanted into mouse brains (104 and 105 cells/mouse).
Mice implanted with TA-MSC cocultured GSCs died earlier than control.
A significantly higher percentage of mice (80%) implanted with low
numbers of TA-MSC cocultured GSCs (102 and 103 cells/mouse) developed
tumors compared with controls (20-40%) indicating that TA-MSCs
increased the tumorigenicity, or stemness, of GSCs. GSCs mixed with
TA-MSCs formed larger tumors than GSCs mixed with HBMECs or GSCs
alone in an orthotropic xenograft model. Phosphorylation of STAT3 was
increased in GSCs cocultured with TA-MSCs than control and pharmaco-
logical inhibition of STAT3 blocked the TA-MSCs action on GSCs.
TA-MSCs secrete high levels of IL6 and neutralizing antibody against IL6
or knockdown of the IL6 receptor (IL6R) or its coreceptor GP130 in GSCs
abolished the ability of TA-MSCs to increase GSC proliferation and stemness
via inhibition of the STAT3 pathway. In conclusion, TA-MSCs within the
GBM microenvironment enhance the tumorigenic and proliferative
properties of GSCs through the IL6/STAT3 pathway.
CB-43. AN ESSENTIAL ROLE FOR EGFR WILD TYPE
IN EGFRVIII-MEDIATED GLIOMAGENESIS
Li Li, Chin-Rang Yang, Sharmistha Chakraborty, Kimmo Hatanpaa,
Sandili Chauncey, Ameena Jiwani, and Amyn Habib; University of Texas
Southwestern Medical Center, Dallas, TX
EGFR gene amplification and mutation is a signature lesion in glioblas-
toma (GBM). EGFRvIII is the most common EGFR mutation in GBM and
is highly oncogenic. EGFRvIII is usually coexpressed with EGFR wild type
(EGFRwt) in GBM. Previous studies have suggested a role for EGFRwt in
EGFRvIII mediated oncogenicity. In order to study the role of EGFRwt in
EGFRvIII-mediated oncogenicity, we used a tetracycline-inducible model
of EGFRvIII expression in an isogenic GBM cell line that also expresses
endogenous EGFRwt. To perturb EGFRwt signaling, we either silenced or
overexpressed wild-type EGFR in U251MG cells expressing
tetracycline-inducible EGFRvIII. Silencing the wild-type EGFR resulted in
a striking inhibition of EGFRvIII-induced tumorigenicity in an orthotopic
mouse model while increasing EGFRwt resulted in accelerated
EGFRvIII-mediated tumor formation. EGFRwt in the absence of EGFRvIII
had only a weak tumorigenic effect. To examine the effect of EGFRwt in
EGFRvIII-mediated signal transduction, we conducted gene expression
analysis in tetracycline-induced EGFRvIII-expressing cells with silenced
EGFRwt, low endogenous EGFRwt, and overexpressed EGFRwt.
Consistent with the biological phenotype, we found that the level of EGFR
wild-type expression has a profound effect on EGFRvIII signaling with
major shifts in gene expression profiles. In general, the signal transduction
profile of EGFRvIII signaling in the presence of EGFRwt includes a higher
number of genes involved in cell proliferation compared to cells with silenced
EGFRwt. In addition, in the presence of EGFRwt the top canonical pathway
activated is “the role of tissue factor in cancer”. This highly oncogenic
pathway is not activated by EGFRvIII in cells with silenced EGFRwt.
Thus, our studies strongly suggest an important role for EGFRwt in
EGFRvIII signaling and may help to identify key EGFRvIII effector signals.
CB-44. A NOVEL MECHANISM OF GLIOMA RESISTANCE
TO ONCOLYTIC VIROTHERAPY: IFN-INDUCED ISGYLATION
BY HDAC6
Tran Nguyen, Hiroshi Nakashima, and E. Antonio Chiocca; The Ohio State
University Medical Center, Columbus, OH
Novel strategies, including oncolytic viral (OV) therapy using con-
ditionally replicating virus, have shown promise in various neurological
tumors, but there is resistance to the lytic effect of the OV. We have been
attempting to identify interferon-response pathways and genes that may be
important in this response. In this study, we hypothesized that one
interferon-stimulated gene (ISG15) was important in this cellular antiviral
response through its interactions/ binding with a particular histone deacety-
lase (HDAC6), which also participates in antiviral response. METHODS: To
investigate the relationship between HDAC6 and ISG15, enzyme overexpres-
sion was induced in U251 glioma cells under IFNb treatment. Analyses were
performed using coimmunoprecipitation assay. RESULTS: We confirmed the
binding of HDAC6 to ISG15, and also found that HDAC6 was capable of
binding to ISG15 enzymes (UbE1L, UbcH8 and HERC5), suggesting that
HDAC6 is involved in ISGylation mediation. We then proceeded to identify
the binding region of ISG15 E1-E3 enzymes on HDAC6. CONCLUSION:
The novel discovery of HDAC6-ISG15 interaction and ISGylation in viral
infection may be important in enhancing glioma cell responses against the
OV by providing a previously unknown effector mechanism of interferon
signaling.
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CB-45. USE OF DOXORUBICIN AND DOXORUBICIN/
IMIPRAMIME BLUE COLOADED NANOPARTICLES YIELDS
SURVIVAL IN AGGRESSIVE HUMAN GLIOBLASTOMA IN MICE
Jenny Munson1, Revaz Machaidze2, Milota Kaluzova2, Ravi Bellamkonda1,
and Costas G. Hadjipanayis2; 1Georgia Institute of Technology, Atlanta,
GA; 2Winship Cancer Institute, Emory University, Atlanta, GA
Glioblastoma invasion is a major reason for recurrence after treatment.
Recently, we saw in a rat glioblastoma model (RT2) that combination of
doxorubicin and imipramine blue, a novel anti-invasive agent that acts via
inhibition of Nox4, enhances survival as compared to doxorubicin alone.
In this study we use convention enhanced delivery (CED) of doxorubicin
(DXR) and imipramine blue (IB) and human glioblastoma line transformed
to express the EGFRvIII receptor, which is more clinically relevant than the
rat glioblastoma previously studied. In this study, we used liposomal nano-
particles containing DXR and IB for CED to an aggressive human glioblas-
toma U87MG-EGFRvIII. Mice were intracranially implanted with tumors
into the brains of immunocompromised mice and treated 7 days later via
CED delivery with 5 mL of nanoparticles containing: saline (n ¼ 5), IB
(16 mg, n ¼ 5), DXR (20 mg, n ¼ 8), or IB-DXR (16 mg IB, 20 mg DXR,
n ¼ 8). Mice were monitored by MRI before and after treatment.
Postmortem, brains were sectioned and stained for hematoxylin and eosin.
Further, the combinatorial treatment was tested in vitro on the cell line to
determine any synergistic effects on cell viability. Both the DXR and
IB-DXR groups showed enhanced efficacy by increasing survival times
above control groups (p , 0.001 for each as compared to control using
Mantel-Wilcox test). There was no benefit for codelivery of the IB with
DXR. However, there was complete survival and remission in 3 animals
per group that received the DXR-loaded nanoparticles, indicating a benefit
to this therapeutic in CED against EGFRvIII positive glioblastomas.
However, this data is striking in the ability of the nanoparticles delivered
via CED to yield complete survival in this highly aggressive model of
glioblastoma
CB-46. THERAPEUTIC IMPLICATIONS OF PROTEIN KINASE
CK2 IN GLIOBLASTOMA
Ying Zhang, Braden McFarland, Markus Bredel, and Etty (Tika)
N. Benveniste; University of Alabama at Birmingham, Birmingham, AL
Protein kinase CK2 is a serine/threonine kinase composed of 2 catalytic
subunits (alpha or alpha’) and 2 beta regulatory subunits. CK2 phosphory-
lates over 300 substrates involved in DNA replication, gene transcription,
signal transduction, cell growth, and apoptosis. CK2 expression and activity
is upregulated in tumors including kidney, breast, lung, prostate, and head
and neck cancers, and it has been suggested that a common denominator
of diverse cancer cells may be an addiction to CK2. The NF-kappaB, Wnt,
Notch, PI3K/AKT, and Hedgehog pathways are all positively regulated by
CK2 in a manner that promotes cell survival. We have recently demonstrated
another important function of CK2 as a novel interaction partner of JAK1
and JAK2, which potentiates JAK and STAT-3 activation. Aberrant acti-
vation of the JAK/STAT-3 pathway is implicated in glioblastoma (GBM)
progression, as well as propagation of the stem cell population in GBMs.
We have evaluated the expression/function of CK2 in the context of
GBMs. CK2alpha is overexpressed in brain tissue from GBM patients com-
pared to control tissues. TCGA data reveals gene dosage gains in CK2alpha
in 33% of 219 GBMs. Functionally, we inhibited CK2 expression by use of
siRNA against CK2alpha and beta, and the activity of CK2 by pharmaco-
logical inhibitors such as TBB. These strategies resulted in inhibition of
both constitutive and stimulus-induced JAK2 and STAT-3 activation and
inhibition of STAT-3 target genes such as SOCS3, IL-6, Pim-1, and Mcl-1.
CK2 inhibition also suppressed survival of GBM cell lines as well as
primary GBM xenograft tumors, suppressed colony formation, and
induced apoptosis. CK2 inhibitors are in phase I clinical trials of breast, pros-
tate, and pancreatic cancers as well as multiple myeloma. Pharmacological
inhibition of the JAK/STAT-3 pathway by CK2 inhibitors, which will
likely also negatively impact other signaling pathways, should be considered
for treatment of patients with GBM tumors.
CB-47. GALECTIN-3 SELECTIVELY KILLS TUMOR CELLS
THROUGH THE INTERACTION WITH B1 INTEGRIN VIA
ENHANCED N-GLYCAN-DEPENDENT MECHANISM
Sok-Hyong Lee, Abdessamad Zerrouqi, Fatima Khwaja, Narra S. Devi, and
Erwin G. Van Meir; Emory University, Atlanta, GA
Galectins are a family of animal lectins, which bind beta-galactose
moieties. Galectin-3 (Gal3) is the only chimeric family member of galectins
and consists of a collagen-like N-terminal region and a C-terminal
carbohydrate recognition domain (CRD), which has binding affinity for
galactose and N-acetyllactosamine. We found that extracellular Gal3
shows a tumor-specific apoptotic effect in that a variety of tumor cell types
(malignant glioma, breast, colon, prostate, and lung) are sensitive to
Gal3-mediated killing, while normal cells (fibroblast, endothelial, and astro-
cyte) are not affected. Furthermore, extracellular Gal3 significantly reduces
in vivo tumor volume. We hypothesize that Gal3 selectively kills tumor
cells by interaction with tumor-specific modified cell surface receptor(s).
First, we found that Gal3 kills tumor cells through caspase-9-dependent
apoptotic induction and that their killing is neutralized with lactose, a
Gal3-CRD binding ligand. Second, we identified that Gal3-induced tumor-
specific apoptosis is mediated through Gal3-beta1 integrin interaction
through a couple of affinity assays and beta1 integrin siRNA neutralization.
beta1 integrin has multiple glycans on its extracellular domain. Gal3 is sup-
posed to interact with beta1 integrin through glycans. Third, we discovered
that enhanced Gal3-beta1 integrin interaction is mediated through the aber-
rant N-linked glycans of tumor cells in that the expressions and the activities
of N-acetylglucosaminyltransferase V (MGAT5), a tetraantennary branch-
ing glycosyltransferase, and upstream glycan-branching enzymes such as
beta1, 4 galactosyltransferases (beta4GalT), and beta1, 3 acetylglucosami-
nyltransferase 2 (beta3GnT2) are significantly enhanced in tumor cells.
The manipulation of MGAT5 affects the sensitivity of Gal3-mediated
apoptosis. Our data showed Gal3 selectively kills tumor cells through the
interaction with aberrantly glycosylated beta1 integrin and consequent
induction of caspase 9-dependent apoptosis. This study gives new insight
into the development of selective and safe tumor therapeutics.
CB-48. MATRICELLULAR PROTEIN CYR61 ACTIVATES A
CELLULAR ANTIVIRAL RESPONSE BY BINDING TO INTEGRIN
A6B1 LIMITING ONCOLYTIC VIRAL THERAPY FOR GLIOMA
Amy Haseley, Sean Boone, Jeffrey Wojton, Lianbo Yu, and Balveen Kaur;
The Ohio State University, Columbus, OH
Oncolytic viruses (OV) have been increasingly recognized as an effective
therapy against glioma. The efficacy of this therapy, however, is limited by
the host cellular innate immune response characterized by activation of
type 1 interferons (IFN). We have previously identified a significant induc-
tion of the secreted, extracellular matrix protein Cyr61 following OV
therapy. Here, we tested the impact of Cyr61 in the tumor microenvironment
on OV efficacy. Using glioma cells transiently transfected with Cyr61
plasmid and tetracycline-inducible glioma cell lines that express Cyr61 in
the presence of doxycycline, we show that Cyr61 expression leads to a signifi-
cant reduction in OV transgene expression. Additionally, reduction in OV
transgene expression is also observed in glioma cells plated on purified
Cyr61, and this inhibition is reversed when cells are incubated with neutra-
lizing antibodies specific to Cyr61. Attesting to Cyr61’s effect on viral onco-
lysis, we show that Cyr61 expression reduces viral toxicity and inhibits virus
replication both in vitro and in vivo. Microarray and real-time qPCR ana-
lyses revealed a significant induction of the type 1 IFNs and IFN responsive
genes when cells were induced to express Cyr61; activation of the Jak/Stat
signaling pathway was functionally verified by phosphorylation of Stat1
and Stat2. Employing function-blocking antibodies to various integrin recep-
tors known to bind to Cyr61, we show that neutralization of the alpha6beta1
integrin receptor rescues the Cyr61 mediated OV inhibition. Indeed, we also
show that activation of the alpha6beta1 integrin receptor on glioma cells by
laminin also results in a reduction in OV transgene expression. Collectively,
the results from this study indicate that the interaction of the extracellular
matrix protein Cyr61 with the alpha6beta1 integrin receptor on glioma
cells results in the induction of type 1 interferons, activating an innate
antiviral response to OV and limiting its efficacy.
CB-49. INFLUENCE OF ACID SPHINGOMYELINASE
ON THE BIOLOGY OF GLIOBLASTOMA AND ITS RESPONSE
TO STANDARD THERAPEUTICS
Jeffrey A. Wojton, Jacob Naduparambil, Nicholas Denton,
Arnab Chakravarti, and Balveen Kaur; The Ohio State University,
Columbus, OH
Ceramide is widely known for its influence in cell signaling, specifically in
relation to programmed cell death. Interestingly, ceramide exists in decreased
levels in glioma compared to normal brain, and levels have even been corre-
lated inversely with tumor grade. Ceramide can be generated de novo from
serine and palmitoyl-CoA or by the hydrolysis of sphingomyelin by the phos-
phodiesterase sphingomyelinase. Acid sphingomyelinase (ASM) has been
shown to be activated by numerous stimuli including chemotherapy and
y-irradiation but is significantly downregulated in malignant astrocytomas
compared to normal brain (oncomine analysis p , .001). Furthermore, our
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data show that primary glioma neurosphere cultures express significantly
lower levels of ASM protein compared to traditional serum cultured
glioma cell lines. In this study, we describe the effects of ASM expression
on the biology and therapeutic response of human glioma cells. We
created 2 stable glioma cell lines, which constitutively overexpress ASM.
Although ASM overexpression had no significant effects on proliferation in
vitro, intracranial tumor formation was delayed significantly in vivo (p ,
.01). We also observed significant changes in the migratory and invasive
properties of these cells. Cells overexpressing ASM migrated significantly
less in a standard Boyden chamber assay compared to transfection controls
(p , .005). Invasion was also abrogated as these glioma cells showed signifi-
cant inhibition in their migration through Matrigel-coated Boyden chambers
(p , .005). We next tested the influence of ASM expression on standard
therapeutics. Glioma cells overexpressing ASM were shown to have signifi-
cant sensitivity to temozolomide (p , .001) and radiation in a standard
clonogenic assay (p , .005). This increase in sensitivity was not dependent
on traditional caspase signaling but did result in a reduction of prosurvival
signaling as displayed by diminished levels of phosphorylated AKT post-
treatment. Here, we show for the first time that expression of ASM has sub-
stantial effects on the biology of glioblastoma and its response to therapy.
CB-50. NOVEL PHOSPHORYLATION SITE IN GLIOMA
EXPRESSED GALECTIN-1 MODULATES INVASIVE PHENOTYPE
Charles A. Conrad1, Xu Wang2, Xiaoyang Sheng1, Carol Nilsson3,
Alan G. Marshall4, and Mark R. Emmett5; 1The University of Texas MD
Anderson Cancer Center, Houston, TX; 2Waters Corporation, Milford, MA;
3Pfizer Global Research and Development, San Diego, CA; 4Florida State
University, National High Magnetic Field Laboratory, Tallahassee, FL;
5The University of Texas Medical Branch Galveston, Galveston, TX
High-grade gliomas express high levels of galectins (predominately
Galectin-1, -3, and -7). Galectins comprise a family of carbohydrate-binding
proteins, which bind beta-galactosides. Galectin-1 (Gal-1) is differentially
expressed in normal tissues and tumors. It appears to be functionally poly-
valent and displays a wide range of biological activities. We and others
have previously shown that Gal-1 is highly expressed in high-grade glioma
cell lines and in glioma cancer stem-like cell lines, almost without exception.
It has also been shown that increased Gal-1 expression is highly correlated
with poor patient survival, thus indicating that Gal-1 could represent a
good therapeutic target. Glioma cell motility involves Gal-1-induced
increases in rhoA expression and alterations of the polymerization of actin
cytoskeleton. In a lactose-independent fashion, Gal-1 is recruited from the
cytosol to the cell membrane by H-Ras-GTP with the subsequent stabiliz-
ation of the H-Ras-GTP complex. To date, there have been no reports on
specific phosphorylation sites in Gal-1 to explain the multiple subcellular
and extracellular locations to which the protein can be found. We report
for the first time that a threonine residue appears to be a unique location
of Gal-1 phosphorylation. Furthermore, this phosphorylation event
appears to be associated with a phenotypic shift in glioma cell lines to
promote invasion. In addition to designing siRNA probes to both the 5’-
and 3’- untranslated regions of endogenous Gal-1 mRNA, we also
constructed both dominant negative and positive mutants at this phosphoryl-
ation site to interrogate the phenotypic shifts that this phosphorylation site
confers. Discovery of the specific kinase that is responsible for this phos-
phorylation event could lead to therapeutic approaches to abate or modulate
high-grade glioma invasiveness.
CB-51. INTEGRATIVE ANALYSIS OF GENOME EXPRESSION
AND PROTEIN PROFILING REVEALS MULTIPLE CORE
PATHWAYS AFFECTED BY EFEMP1 IN GLIOMA
Yuanjie Hu, Linskey Mark, and Yi-Hong Zhou Zhou; University of
California Irvine, Irvine, CA
Gliomas are infiltrating primary brain tumors with higher grades charac-
terized by increasing neoangiogenesis and changes of extracellular matrix
components. We carried out a study of EGF containing fibulin-like extra-
cellular matrix protein 1 (EFEMP1) and demonstrated a strong tumor-
suppression function of EFEMP1 partially via suppression of proangiogenic
factor VEGFA expression. Other signaling pathways should be involved that
we are investigating using whole genome oligo expression arrays on RNA
samples of glioma cells with or without EFEMP1 overexpression and phos-
phorylated AKT antibody array on whole cell lysate of the corresponding
cells after a 48-hour serum starvation. The candidate EFEMP1 targets
were further verified by real-time qRT-PCR and western blot. Expression
array showed that EFEMP1 suppressed the expressions of multiple genes
encoding extracellular matrix proteins (FN1, COL4A1, COL6A1,
COL21A1, LAMA4, and LAMB3), extracellular ligands (VEGFA, EGF,
FGF, and EGR2), and membrane receptors (PDGFRA, FGFR2, FGFR3,
EGFR, ITGAV, ITGB1, and IL11RA). Antibody array revealed that
EFEMP1 blocked multiple target protein phosphorylations downstream of
AKT, which was consistent with finding of exogenous EFEMP1 protein in
blocking AKT phosphorylations in multiple glioma cell lines. It includes
FOXO transcription factors, NFKBIA, CHUK, BCL2 protein family that
phosphorylation may ensure glioma cell survival under stressful environ-
ments. EFEMP1 also reduced phosphorylations of PTK2, PTK2B, and
PTK2 downstream target PXN, which together form the FAK signaling
pathway. Overall, data revealed multiple ways of EFEMP1 in suppressing
high grade glioma malignant behaviors, including blockage of AKT- and
FAK-signaling pathways and normalized tumor microenvironment.
CB-52. MOLECULAR DETERMINANTS OF DICHOTOMY
BETWEEN PROLIFERATION AND INVASION OF GLIOMA
CELLS
Harshil Dhruv1, Wendy McDonough1, Nhan Tran1, Brock Armstrong1,
Serdar Tuncali1, Jenny Eschbacher2, Kerri Kislin1, and Michael Berens1;
1The Translational Genomics Research Institute, Phoenix, AZ; 2St. Joseph’s
Hospital and Medical Center, Phoenix, AZ
Classic histological features of glioblastoma include dense proliferative
areas rich in angiogenesis as well as centripetal dissemination of neoplastic
cells into adjacent brain tissue. Distinct transcriptomes are discernable
between GBM cells at the tumor core and invasive rim, and many of the dif-
ferentially expressed genes are co-associated with migration and prolifer-
ation. Our studies of glioma cells from paired core and rim human biopsy
specimens reveal a higher proliferative index (Ki67 Mib-1 IHC score) at
the core as compared to the rim (19 of 35 specimens; p , 0.002). Analysis
of activation states of transcription factors revealed that c-Myc activity is
up in the core while NF-kappaB activity is up at the invasive rim of the
tumor. Immunohistochemical validation using a glioma tissue microarray
containing paired core and rim biopsy specimens showed that
phospho-c-Myc staining in the nucleus was higher in the core than in the
rim for 24 of 39 biopsy specimens scored, whereas phospho-NF-kappaB
was higher in the rim than the core for 30 of 43 biopsy specimens scored.
Depletion of c-Myc expression resulted in an increase in the migration rate
and decrease in the proliferation rate of glioma cells in vitro. Conversely,
inhibition of NF-kappaB by pharmacological inhibitors resulted in a
decrease in the migration and invasion rates of GBM cells in vitro and ex
vivo. However, inhibition of NF-kappaB actually did not increase the
proliferation rate of glioma cells, suggesting that some basal expression
level of NF-kappaB is necessary to negate pro-apoptotic characteristics of
c-Myc and to drive the malignant phenotype of the glioma cells. The “Go
versus Grow” hypothesis suggests cell proliferation and migration are
temporally exclusive behaviors and tumor cells postpone cell division
for migration. Our findings argue that differential suppression/activation
of c-Myc and NF-kappaB underlies the shift of glioma cells from growing
to going.
CB-53. FOXO CROSS-REGULATION OF TSC1-MTORC1
IN GLIOMA
David Plas1, Catherine Gallo1, Keith Stringer2, Ady Kendler1, and
Christopher McPherson1; 1University of Cincinnati, Cincinnati, OH;
2Cincinnati Children’s Hospital, Cincinnati, OH
The Forkhead Box subclass O (FOXO) transcription factors govern the
cellular programs for quiescence, redox stress responses, and apoptosis.
We show that FOXOs regulate glycolysis through transcriptional control
of the TSC1 tumor-suppressor protein. FOXO inactivation reduced TSC1
expression in multiple cell types, triggering mTOR complex 1 (mTORC1)
activation and increased cellular glycolysis (the Warburg effect). FOXO
inactivation was counteracted by the allosteric inhibitor of mTORC1, rapa-
mycin, reducing glycolysis. Oncomine analysis suggested that decreased
TSC1 mRNA expression frequently occurs in glioma. In mRNA harvested
from gliomas, we observed a frequent reduction in TSC1 mRNA expression,
which correlated with decreased FOXO3 mRNA (R2¼0.779, p , 0.0001).
Immunoblot analysis of a small panel of tumors suggested increased acti-
vation of mTORC1 in samples upon inhibitory phosphorylation of
FOXOs. Together the data indicate that FOXO inactivation contributes to
mTORC1 activation and altered metabolism in glioma. This suggests that
FOXO inactivation contributes to mTOR activation and therefore
re-activating FOXO may be a target for treatment of gliomas.
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CB-54. DIFFERENCES IN FOREBRAIN AND SPINAL CORD
TUMORS REFLECT UNIQUE MICROENVIRONMENTAL
RESPONSES TO PARACRINE STIMULATION IN PDGF-DRIVEN
MODELS OF GLIOMA
Michael A. Castelli, Jason A. Ellis, Marcela Assanah, Jeffrey N. Bruce,
Peter Canoll, and Alfred Ogden; Columbia University, New York, NY
Injecting PDGF-expressing retrovirus into the subcortical white matter of
adult rats induces the formation of brain tumors with the histological
features of GBM, including diffuse infiltration of tumor cells, glomeruloid
vascular proliferation, and pseudopalisading necrosis. In contrast, when
the same retrovirus is injected into the spinal cord of adult rats, the resulting
tumors do not resemble GBM but rather showed a unique histology charac-
terized by nests of tumor cells separated by a dense vascular network without
areas of necrosis. To examine if these differences were intrinsic to the tumor
cells or owing to the effects of the microenvironment, we performed a series
of tumor cell transplantation studies. Cells were isolated from forebrain or
spinal cord tumors and then injected into the forebrain or spinal cord of
naive adult rats. Injections into the forebrain by cells isolated from either
forebrain or spinal cord tumors formed secondary tumors with a mor-
phology closely resembling GBM. In contrast, cell injections into the
spinal cord by either spinal cord or forebrain tumor cells resulted in
tumors that resembled the retrovirus driven spinal tumors. These results
suggest that microenvironment is affecting the tumor histology. To explore
the nature of these microenvironmental influences, we examined the ratio
between recruited glial progenitors expressing PDGFRalpha and pericytes
expressing PDGFRbeta, both of which respond to paracrine PDGF-BB
stimulation from the retrovirus infected cells. Tumors generated in the fore-
brain contained PDGFRalpha+ recruited glial progenitor populations that
far outnumbered the PDGFRbeta+ pericytes, whereas in the spinal cord
tumors the pericytes outnumbered the recruited glial progenitors. Thus,
the forebrain and spinal cord tumors differ in the relative abundance of
PDGF responsive cells (glial progenitors and pericytes) that are being
recruited from the microenvironment, and these differences in cellular com-
position give rise to differences in tumor histology.
CB-55. NEUTROPHILS PROMOTE THE MALIGNANT GLIOMA
PHENOTYPE IN VITRO
Ji Liang, Yuji Piao, and John F. deGroot; The University of Texas MD
Anderson Cancer Center, Houston, TX
Solid tumors, including glioblastoma, contain large populations of cancer-
related inflammatory cells. Among these inflammatory cells, infiltration of
tumor-associated neutrophils (TANs) has been found to be significantly cor-
related with glioblastoma grade. However, the potential roles of TANs and
the molecular mechanisms by which these inflammatory cells promote
glioma growth are not well established. In this study, we found increased
neutrophil infiltration into tumor cells during glioma xenograft progression
in vivo. To determine the effect of neutrophils on glioma cells, we next took
advantage of an in vitro coculture model to mimic communication between
these 2 types of cells. Our data demonstrate that neutrophils increased the
proliferation rate of stem cell-like cells (GSCs). Condition media (CM) col-
lected from cultured neutrophils had a similar effect, suggesting that
growth factor secretion by neutrophils exerts this paracrine effect. After
GSCs were cultured in CM for 48 hours, there was a statistically significant
increase in the proportion of cells in the S + G2/M compartment and a con-
comitant decrease in apoptosis as measured by PI staining. We next evalu-
ated the impact of neutrophils on glioma invasion. CM from neutrophils
significantly increased GSC transwell migration compared to controls.
cDNA microarray and immunoblotting experiments confirmed that the
expression levels of Cyclin D2 and c-Myc were upregulated in GSCs cocul-
tured with neutrophils. This upregulation could be abrogated by MEK/
ERK inhibitor (U1026), suggesting a possible role of the MAPK pathway
in the proliferative-promoting effects of neutrophils on GSCs. Collectively,
these data suggest that recruitment of neutrophils could promote glioma
proliferation and invasion. Targeting granulocytes may be an effective
approach to inhibit the glioma malignant phenotype.
CB-56. NICOTINAMIDE-N-METHYLTRANSFERASE IN
GLIOBLASTOMA CONFERS RESISTANCE TO RADIATION
TREATMENT AND EXPRESSION LEVEL INVERSELY
CORRELATES WITH SURVIVAL
Nicolaus Gordon, Disha Patel, Arnab Chakravarti, and
Kamalakannan Palanichamy; The Ohio State University, Columbus, OH
PURPOSE: Glioblastoma multiforme (GBM) is the highest grade and most
aggressive form of glioma. Average patient survival is about 14 months after
diagnosis. The relative resistance to conventional therapy displayed by GBM
leaves opportunity for vast improvement in survival. Elucidating mechan-
isms of radiation resistance or uncovering novel targets to sensitize tumors
to radiation could significantly benefit patient outcomes. Nicotinamide-
N-methyltransferase (NNMT) is an enzyme involved in the nicotinamide
pathway as well as in the metabolism of drugs and xenobiotic compounds.
While the exact role NNMT plays in the malignant phenotype is poorly
understood, it has been investigated for its potential use as a prognostic
marker or therapeutic target in other cancers. NNMT is highly expressed
in glioblastoma compared to either lower grade astrocytomas or normal
brain tissue. Furthermore, Kaplan-Meier plots from publically available
clinical data sets have shown that relatively higher NNMT expression is cor-
related with adverse patient outcome. Gaining a better understanding of
NNMT’s role in GBM could uncover exciting advances in neuro-oncology.
EXPERIMENTAL DESIGN: We explored the expression profile of
NNMT in established (ATCC) and in our panel of patient-derived primary
GBM cell lines. We generated an isogenic, in vitro model by knocking
down as well as overexpressing NNMT in U87 cells. We conducted
various functional experiments such as MTS assay, clonogenic survival
assay, annexin V, ATP assay, comet assay, and western blotting analysis.
In vivo experiments were also used to determine differences in relative
tumorigenicity. RESULTS AND CONCLUSION: Intracranial implantation
of NNMT knockdown cells in mice showed a delayed tumor growth com-
pared to NNMT overexpression cells. Silencing NNMT leads to an enhanced
sensitivity to radiation in vitro, whereas cells overexpressing NNMT are
more resistant to radiation. These results merit further investigation into
NNMT’s role in GBM treatment resistance.
CB-57. THE REGULATORY ROLE OF MICRORNA
IN MALIGNANT GLIOMAS AND THEIR POTENTIAL ROLE
AS NOVEL TUMOR BIOMARKERS
Shawn Hervey-Jumper, Anthony Wang, Xiaobing He, Thant Zhu,
Jason Heth, Karin Muraszko, and Xing Fan; University of Michigan,
Ann Arbor, MI
INTRODUCTION: Glioblastoma multiforme (GBM) is the most common
malignant brain tumor in adults. MicroRNAs (miR) are important regula-
tors of gene expression through posttranscriptional silencing of target
mRNA. MiR roles in cell proliferation, invasion, angiogenesis, and glioma
stem cell activity are unknown. METHODS: Using RNA extracted from
GBM patient tumor specimens, miR 338-3p expression, relative to normal
brain and control serum, was examined using RT PCR. Regional miR
expression within a single tumor was identified. A DNA sequence containing
the hsa-miR-338-3p locus was amplified and cloned into a lentiviral vector,
then transduced into GBM established neurospheres, primary patient
samples, and human neuronal stem cells. MiR 338-3p and its downstream
target expression was assessed by RT PCR and western blot. GBM neuro-
sphere formation and cellular proliferation were examined in vitro and in
vivo. Using serum obtained from GBM patients, RNA was extracted identi-
fying miR levels relative to normal controls. RESULTS: Overexpression in
miR 338-3p is associated with decreased glioblastoma proliferation, cellular
invasion, and neurosphere formation both in vitro and in vivo. MiR 338-3p
displays decreased expression levels in the tumors core with increased
expression at the tumor’s rim and migrating edge. MiR 338-3p overexpres-
sion induces cellular apoptosis as determined by cleaved caspase 3 expression
levels in GBM. MiR 338-3p overexpression shows no effect on proliferation
in human neuronal stem cells; however, it does result in induced neuronal
differentiation as determined by TUJ1 expression levels. MiR 338-3p
targets histone deacetylase 4 (HDAC4). MiR 542-5p is detectable in the
serum of glioma patients as well as normal surgical controls. Serum miR
542-5p levels seem to correlate with response to therapy. CONCLUSION:
MiR 338-3p inhibits GBM neurosphere growth and invasion both in vitro
and in vivo through reducing proliferation and inducing apoptosis possibly
via targeting of HDAC4.
CB-58. ENHANCED ONCOLYTIC HSV-1 THERAPY BY HDAC6
INHIBITION
Hiroshi Nakashima, Tran Nguyen, and E. Antonio Chiocca; The Ohio State
University Medical Center, Columbus, OH
INTRODUCTION: Oncolytic viruses (OVs) have been used as a treat-
ment modality for malignant gliomas, yet efficient replication of OVs
to tumor regions may be a challenge owing to innate immune responses
to gliomas. Previously, we have shown that pan-HDAC inhibitors
can enhance HSV-1 replication in human glioma cells by escaping
IFN-mediated antiviral effects (Otsuki et al., Mol. Therapy 2008). In this
study, we hypothesized that a novel glioma defensive mechanism against
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oncolytic HSV1 is provided by histone deacetylase 6 (HDAC6). RESULTS:
Catalytic inactivation of HDAC6 by pharmacological inhibitor or shRNA
knockdown increased oHSV1 replication. Pharmacologic inhibition of
HDAC6 induced hyperacetylation of alpha-tubulin and enhanced viral
capsid trafficking toward the nucleus while impairing lysosomal encapsula-
tion of the HSV-1 capsids in human glioma cells. Furthermore, HDAC6 inhi-
bition suppressed interferon-stimulated genes (ISGs) expression upon HSV-1
infection, suggestive of HDAC6 function involving antiviral immune
response. CONCLUSION: Our data show for the first time that HDAC6 is
a novel antiviral mechanism in gliomas and uncovers pharmacological
maneuvers to help viral replication.
CB-59. LYN PROMOTES MALIGNANT GLIOMA CELL
SURVIVAL BY PROMOTING AUTOPHAGY
Wei M. Liu1, Ping Huang1, Sandhya Rani1, Michelle R. Stettner2,
Stewart Jerry1, Qun Dai2, John Kappes2, Russell Tipps1, and
Candece L. Gladson1; 1Cleveland Clinic, Cleveland, OH; 2University of
Alabama at Birmingham, Birmingham, AL
We reported previously that Lyn activity and protein are significantly elev-
ated in glioblastoma (GBM) biopsies. Here, we investigated the function of
Lyn in regulating the survival of GBM cells by expressing a dominant
negative-Lyn (DN-Lyn) or a constitutively active-Lyn (CA-Lyn) construct,
followed by analyses of cell survival and proliferation. Using both monolayer
viability assays in serum-free media and soft-agar growth assays, we found
that expression of DN-Lyn resulted in decreased survival and decreased
colony number, whereas expression of CA-Lyn resulted in increased survival
and increased colony number as compared to control LV cells. To determine
whether Lyn regulates cell-cycle progression, we labeled cells with BrdU
followed by cell-cycle analysis; CA-Lyn increased the percentage of cells in
G0/G1 and decreased the percentage of cells in S phase relative to the
control cells consistent with quiescence. We also investigated apoptosis
and found an increase in annexin V labeling with expression of DN-Lyn
and a significant decrease in annexin V labeling with CA-Lyn. To evaluate
whether Lyn promotes autophagy, we blotted for LC3B protein in lysates
and found an increase in the normalized LC3BII band in the CA-Lyn
lysates and a decrease in the DN-Lyn lysates, suggesting Lyn promotes survi-
val through autophagy in the GBM cells. Furthermore, when CA-Lyn cells
were propagated in the nude mouse brain, a dramatic increase in tumor
volume was seen, accompanied by a decrease in tumor cell TUNEL-labeling,
and a decrease in tumor volume was seen in the DN-Lyn GBM tumors with
an increase in TUNEL-labeling. Akt has recently been shown to regulate
autophagy; we found an increase in Akt activity in the CA-Lyn cells
suggesting CA-Lyn may promote autophagy and cell survival through an
increase in Akt activity. In summary, Lyn promotes autophagy of GBM
cells thereby enhancing survival both in vitro and in vivo.
CB-60. DEFINING AND TARGETING TUMOR SIGNALING
NETWORKS IN NF1 DEFICIENT GLIOBLASTOMA
Debyani Chakravarty1, Alicia Pedraza1, Dimpy Koul2, W.K. Alfred Yung2,
and Cameron W. Brennan1; 1Memorial Sloan-Kettering Cancer Center,
New York, NY; 2The University of Texas MD Anderson Cancer Center,
Houston, TX
Glioblastoma (GBM) is a genetically heterogeneous group of tumors that
remains largely refractory to treatment. The Cancer Genome Atlas (TCGA)
has described 4 transcriptomal signatures of primary GBM, 3 of which—
classical, proneural, and mesenchymal—are associated with alterations in
EGFR, PDGFR, and NF1, respectively. NF1 loss—either by mutation, del-
etion, and/or underexpression—is found in up to 25% of primary GBM
and is associated with sarcomatous histology, suggesting that these tumors
represent a distinct subclass of GBM. NF1 deficiency in other cancer types
has been associated with diverse pathway dysregulation and, in some
cases, sensitivity to MAP kinase pathway inhibition. We sought to investi-
gate this in GBM. Using reverse phase protein array technology (RPPA),
we have profiled signaling network proteins in a panel of 80 GBM and
lower grade astrocytomas and compared patterns of activation with NF1
status determined by resequencing, array-CGH, mRNA expression, and
western blot. Consistent with NF1-mediated regulation of the MAPK
pathway, we observed upregulation of pErk and pMEK and modulation of
other signaling nodes such as STAT3, Src, p38, and mTOR target S6K in
NF1-deficient tumors. We defined the basal activation state of key signaling
nodes in NF1-expressing versus deficient tumor sphere lines and assessed the
comparative effects of MEK inhibitor PD98059 biochemically and in terms
of their growth and viability. These findings will help inform the selection of
candidate “synthetic lethal targets” for synergistic inhibition in MEK-i
resistant NF1-deficient GBM.
CB-61. IDENTIFICATION OF BCL2L13 AS A NOVEL GBM
ONCOPROTEIN
Samuel A. Jensen, Janina Luciano, Andrea Calvert, Varun Nagpal, and
Alexander Stegh; Northwestern University, Chicago, IL
Using in silico analysis of 272 GBM samples in the TGCA data set to find
important cell death mechanisms in gliomapathogenesis, we identified differen-
tial expression of the novel Bcl2-like13 protein (Bcl2L13). Bcl2L13 shares sig-
nificant structural homology with Bcl-2 and Bcl-xL, but contains a unique 250
amino acid sequence that may point to unique, nonclassical functions. Several
studies have shown that Bcl2L13 expression correlates with increased che-
motherapeutic resistance and unfavorable treatment outcome in leukemia
and ZIC1-driven liposarcomas. Those clinical data suggest that Bcl2L13
likely acts as an oncoprotein in multiple cancers and may act in a similar
manner in GBM. Using qRT-PCR and immunohistochemical analyses, we
found that Bcl2L13 was highly overexpressed in .90% of GBM samples but
was absent in adjacent normal brain. Using RNAi-loss and cDNA complemen-
tation studies in glioma cell lines, we determined that Bcl2L13 potently inhibits
therapy-induced apoptosis by inhibiting mitochondrial outer membrane per-
meabalization (MOMP) and postmitochondrial caspase-3 and -7 cleavage,
likely acting in a similar manner as canonical Bcl-2 family proteins. To study
the impact of Bcl2L13 on the progression of gliomagenesis in vivo, we orthoto-
pically injected glioma cell lines with enforced expression of Bcl2L13-targeting
shRNAs into immunocompromised SCID mice. Strikingly, neutralization of
Bcl2L13 signaling increased overall glioma-free survival, which was associated
with enhanced intratumoral apoptosis and decreased proliferative indices. To
molecularly elucidate the mechanism by which Bcl2L13 exerts its anti-
apoptotic effects, we performed a yeast 2 hybrid screen and identified a select
number of tumor suppressors and oncoproteins including ceramide synthase
2 (CerS2), a regulator of MOMP, and O-6-methylguanine-DNA methyltrans-
ferase (MGMT), an important prognostic indicator of temozolomide effective-
ness, as Bcl2L13 interaction partners. Taken together, these results reveal that
Bcl2L13 represents a novel anti-apoptotic, Bcl-2-like GBM oncoprotein that
inhibits apoptosis progression and promotes tumor growth by impacting
mitochondrial membrane physiology.
CB-62. FREQUENT EPIGENETIC INACTIVATION OF XAF1
AND ITS IMPLICATION FOR TUMOR CELL RESISTANCE
TO APOPTOTIC STRESSES IN HUMAN GLIOBLASTOMA
Shin-Hyuk Kang1, Mi Ok Yu1, Min-Goo Lee2, Sung-Gil Chi2, and
Yong-Gu Chung1; 1Anam Hospital, Korea University, Seoul, Republic of
Korea; 2School of Life Sciences and Biotechnology, Korea University, Seoul,
Republic of Korea
OBJECTIVE: XIAP-associated factor 1 (XAF1) is a tumor suppressor that
has been known to exert proapoptotic effects by interfering with the
caspase-inhibiting activity of XIAP. In this study, we investigated the XAF1
status and its role in human glioblastoma. METHODS: Expression and pro-
moter methylation status of XAF1 was examined using 16 human glioblas-
toma tissues and 7 cell lines. The effect of XAF1 on tumor growth was
determined by flow cytometric analysis of cell proliferation and apoptosis
and colony formation assay. RESULTS: While XAF1 transcript was easily
detectable in all normal brain tissues we tested, its expression was undetect-
able or very low in 86% (6 of 7) of cell lines and 75% (12 of 16) of primary
tumors. Moreover, XAF1 reduction was significantly more common in high-
grade tumors versus low-grade tumors. Following treatment with the
demethylating agent 5-aza-dC, hypermethylation at 7 CpG sites in the 5’
proximal region of the XAF1 promoter was highly prevalent in glioblastomas
versus normal tissues and tightly associated with reduced gene expression.
XAF1 expression suppressed tumor cell growth and enhanced cellular
response to apoptotic stresses in a XIAP-independent manner, while knock-
down of its expression protected cells from the stresses. Intriguingly, it was
found that XAF1 expression is upregulated by chemotherapeutic drugs,
such as temozolomide and etoposide, and XAF1 induction leads to Erk sup-
pression. Furthermore, under apoptotic stress conditions, Erk elevation by
XAF1 depletion was associated with enhanced tumor cell resistance to apop-
totic stresses. In addition, the apoptosis-sensitizing effect of XAF1 was attenu-
ated by ectopic overexpression of Erk, indicating that XAF1’s proapoptotic
effect is associated with its ability to inhibit Erk elevation under apoptotic
stress condition. CONCLUSION: Collectively, our study demonstrates that
epigenetic alteration of XAF1 is frequent in human glioblastoma and may
contribute to the malignant tumor progression.
CB-63. CLASSIFICATION OF ADULT MALIGNANT GLIOMA
SUBTYPES WITH AN ACTIVATED AND OPERATIONAL
HEDGEHOG PATHWAY
Michael K. Cooper, Juan G. Valadez, and Vandana K. Grover; Vanderbilt
Medical Center, Nashville, TN
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The Hedgehog (Hh) signaling pathway regulates the growth of a subset of
adult malignant gliomas. Thus, correlating the operational status of the Hh
pathway with classifications of malignant glioma subtypes might enhance
the clinical utility of monitoring and targeting this pathway in patients.
Our prior studies indicating that Hh pathway activation is confined to
WHO grade II and III astrocytomas and oligodendrogliomas are at odds
with other reports of pathway activation in grade IV glioblastoma. To evalu-
ate further the subtypes of malignant glioma in which the Hh pathway is
operational, we conducted a more extensive survey of adult glioma speci-
mens and primary glioma cell cultures and included mutational analysis of
the IDH1 and IDH2 genes. Here, we report that the Hh pathway is com-
monly activated and operational in astrocytomas and oligodendrogliomas
and rarely in glioblastoma. Screening for mutations in IDH1 and IDH2
within WHO Grade II and III gliomas does not enhance the predictive
impact for identifying Hh-responsive gliomas beyond the use of histological
classification. With respect to glioblastoma, however, we found that an oper-
ational Hh pathway is confined to clinically defined secondary GBM and
primary GBM bearing IDH mutation.
CB-64. MICRORNA-182 ACTS AS A CHEMOSENSITIZER
IN GBM BY REPRESSING BCL2L12
Foteini M. Kouri1, Lynda Chin2, and Alexander H. Stegh1; 1Northwestern
University, Chicago, IL; 2Dana-Farber Cancer Institute, Boston, MA
Glioblastoma multiforme (GBM) is the most prevalent and aggressive
brain tumor, exhibiting high mortality rates and increased resistance to
current forms of treatment. GBM development has been linked to deregula-
tion of several signaling cascades involved in cell proliferation and apoptosis.
Bcl2-like 12 (Bcl2L12) is a multifunctional glioma oncoprotein that is over-
expressed in the majority of GBM and plays pivotal roles in driving tumor
progression and resistance to therapy-induced apoptosis. Mechanistically,
we identified Bcl2L12 as a potent inhibitor of postmitochondrial effector cas-
pases and the p53 tumor suppressor. To begin to molecularly dissect cellular
mechanisms that regulate Bcl2L12 expression and function, we interrogated
whether Bcl2L12 is under the control of microRNAs (miRs). In silico analy-
sis of 272 primary GBM samples of the multidimensional TCGA data set
aimed to identify miRs displaying expression levels that anticorrelate with
Bcl2L12 mRNA abundance, as such candidates represent potential
Bcl2L12-targeting miRs. This oncogenomic approach revealed a significant
anticorrelation between Bcl2L12 mRNA and miR-182 expression, preferen-
tially in the proneural subtype, a GBM class with established low Bcl2L12
genomic amplification and mRNA expression and a trend toward longer sur-
vival compared to patients with mesenchymal, neural, or classical tumors.
Enforced expression of miR-182 in various glioma cell lines confirmed
robust downregulation of Bcl2L12 mRNA and protein levels, identified the
miR-182 binding site within the 3’UTR of Bcl2L12, and documented that
miR-mediated downregulation of Bcl2L12 is highly specific for miR-182,
but not for other related miRs, such as miR-96 and miR-183. Finally,
transfection of pre-miR-182 significantly sensitized cells towards various
antiglioma therapeutics via enhancement of effector caspase activation.
Taken together, our studies confirmed a Bcl2L12- miR-182 axis on genetic
and biological levels and identified miR-182 as a potential therapeutic
agent to halt GBM progression.
CB-65. SIGNIFICANTLY ALTERED PLASMA LEVELS OF
SOLUBLE TNFR1 AND TNFR2 IN GLIOBLASTOMA PATIENTS
Manmeet S. Ahluwalia, Divya Khosla, Robert J. Weil, Mary McGraw,
Ping Huang, Richard Prayson, Amy Nowacki, Gene H. Barnett, and
Candece Gladson; Cleveland Clinic, Cleveland, OH
Plasma biomarkers are needed to identify patients with recurrent glioblas-
toma (GBM) and to detect lack of a response to therapy. Soluble TNFR1 and
TNFR2 (sTNFR1 and sTNFR2) in blood are thought to bind and inhibit
TNF alpha; however, in several other types of cancer plasma/serum levels
of TNF alpha do not correlate with sTNFR1/2, suggesting the levels of
sTNFR1/2 are not reflective of the levels of TNF alpha. We evaluated the
levels of sTNFR1 and sTNFR2 in the plasma of 29 GBM patients as com-
pared to 19 normal controls by specific ELISA analyses. We found a signifi-
cant increase in the level of sTNFR1 in the GBM patients (mean, 1208 pg/
ml+823; mean+ SD) compared with normal controls (mean, 878 pg/ml+
288; p ¼ 0.0335, Wilcoxon rank-sum test). Surprisingly, we also found a sig-
nificant decrease in the level of sTNFR2 in the GBM patients (mean, 2658
pg/ml+1357) compared with normal controls (mean, 3572 pg/ml+927;
p ¼ 0.0004, Wilcoxon rank-sum test). In several other cancers, sTNFR2
has been reported to be significantly elevated in plasma/serum and to be
associated with tumor depth and metastasis. Our finding of reduced
sTNFR2 in GBM may in part reflect the absence of metastatic tumor. No
correlation of survival with the level of sTNFR1 or of sTNFR2 was found;
we are expanding our sample numbers (power) to further examine this. In
summary, measurement of plasma/serum levels of sTNFR1 and sTNFR2
may be useful biomarkers to follow GBM patients.
CB-66. beta-CATENIN/TCF4 REGULATES BIOLOGICAL
BEHAVIOR BY REGULATING AKT1/AKT2 AND MMIR-21
IN HUMAN BRAIN GLIOMA
Chunsheng Kang, Jian Zou, Fengming Lan, Xiao Yue, Zhendong Shi,
Kailiang Zhang, Lei Han, and Peiyu Pu; Tianjin Neuro-logical Institute,
Tianjin Medical University General Hospital, Tianjin, China
It is very clear that the Wnt/beta-catenin pathway takes part in some
pathologic process such as tumorigenesis, cell cycle, development, and differ-
entiation. beta-catenin and Tcf-4 are important transcription factors in the
Wnt/beta-catenin pathway; they form a beta-catenin/Tcf-4 complex to regu-
late the expression of a series of proto-oncogenes at the transcriptional level.
A number of studies have found that the wnt pathway closely links with
many pathways, such as the EGFR-PI3K-AKT pathway. Preliminary work
in our laboratory found that aspirin can inhibit the activity of beta-catenin
and Tcf-4 in glioma, but it does not affect expression of the beta-catenin
and Tcf-4 protein. After treating with beta-catenin/Tcf-4 inhibitors in
glioma cells and detecting the downstream target genes, it was found that
AKT1, AKT2, miR-21, EGFR, c-mycare all decreased. TOP/FOP luciferase
reporter experiments prove the transcriptional activity of beta-catenin/Tcf-4
complexes; after treatment with aspirin or beta-catenin/Tcf-4 inhibitors, flu-
orescence levels were found to decrease after treatment. To further determine
the transcription start sites of promoter region between beta-catenin/Tcf-4
complex with AKT1, AKT2, and miR-21, we constructed plasmids of the
wild type and mutant type, which contained expression luciferase in the pro-
moter region of AKT1, AKT2, and miR-21, to determine the specific binding
site that bind to AKT1, AKT2, and miR-directly.(Supported by NSFC
30971136,NCET-07-0615, TJSTC 09JCZDJC17600). *Chunsheng Kang,
PhD, Laboratory of Neuro-Oncology, Tianjin Neurological Institute,152,
Anshan Road, Heping, Tianjin 300052, PR China. Fax: 022-27813550.
Tel:022-60362662. E-mail: kang97061@yahoo.com
CB-67. DIFFERENTIAL EXPRESSION OF AQUAPORIN 1
AND 4 IN HUMAN GLIOMAS
Brian F. Seaman and Nam D. Tran; H. Lee Moffitt Cancer and Research
Center, Tampa, FL
Cerebral edema is a common feature of primary brain gliomas and
contributes to significant morbidity and mortality. Additionally, increased
cerebral edema is often associated with more aggressive tumors. The
mechanisms of cerebral edema are complex and are mediated in part
by aquaporin proteins (AQP). AQP channels play a role in water homeo-
stasis. AQP-1 and AQP-4 expression has been demonstrated in glioma
astrocytes. Furthermore, increased expression of AQP-1 and AQP-4 has
been reported in human glioblastoma. These findings suggest a regulatory
role for AQP in the tumor-associated edema. Nevertheless, previous
studies have failed to demonstrate a causal relationship between AQP
upregulation and glioma histologic grade. We hypothesize that increased
expression of AQP-1 and AQP-4 is directly correlated with the degree of
tumor-associated edema and the tumor histologic grade. METHODS:
Formalin-fixed, paraffin-embedded brain tumor specimen, including low-
grade astrocytomas, low-grade oligodendrogliomas, anaplastic oligoden-
drogliomas, anaplastic astrocytomas, and glioblastoma, were analyzed
(n ¼ 20). Immunohistochemistry was used to assess tumor expression of
AQP-1 and -4. These specimens were double stained with GFAP, NSE,
vWF, and VEGF to colocalize to cells of astrocytic, neuronal, and endo-
thelial origin. Secondary analysis correlated the expression of AQP to the
volume of extracellular brain edema based on preoperative MR imaging.
RESULTS: Immunohistochemical analysis demonstrated a direct corre-
lation between increased AQP expression and higher tumor histologic
grade. Additionally, upregulation of AQP is directly correlated with
volume of extracellular brain edema. CONCLUSION: This project
establishes a framework for future research involving cerebral aquaporin
channels in human gliomas. We demonstrate an association between
AQP-1 and AQP-4 expression and aggressive glioma tumor phenotype
and tumor-associated cerebral edema volume. This improved understand-
ing of AQP’s role in tumor-associated edema may lead to new thera-
peutic targets for the reduction of brain edema and its associated
comorbidities.
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CB-68. NHERF-1 FUNCTIONS AS A MOLECULAR SWITCH
BETWEEN CELL MIGRATION AND PROLIFERATION
IN GLIOBLASTOMA
Wendy McDonough, Harshil Dhruv, Kerri Kislin, and Michael Berens;
TGen, Phoenix, AZ
Genetic alterations in malignant gliomas affect cell proliferation and cell-
cycle control and are currently the targets of most chemotherapeutic agents.
However, the efficacy of treating advanced glial tumors with adjuvant thera-
pies remains largely unsuccessful owing to the inability to effectively target
invading cells. Primary glioblastomas that arise de novo often show amplifi-
cation and overexpression of EGFR (.50% of glioblastomas). As with many
tumors, a temporal dichotomy between growth and invasion is evident;
however, key intracellular factors responsible for regulating the ‘switch’
between proliferation and migration remain poorly discerned. We previously
have shown that the Na + /H+ exchanger regulatory factor (NHERF-1)
gene was significantly overexpressed in the invading rim of the tumor speci-
mens when compared to matched, more proliferative, core regions. In this
study, we demonstrated that NHERF-1 functions as a critical ‘switch’ for
GBM cells in the differential adoption of a migratory versus proliferative
phenotype, potentially regulating the EGFR signaling pathway.
Specifically, depletion of NHERF-1 expression by siRNA oligonucleotides
suppresses GBM migration but surprisingly increases cell proliferation. In
addition, depletion of NHERF-1 expression increases Grb2 binding to the
EGFR receptor and enhances MAPK activation. In contrast, inhibition of
Grb2 expression by siRNA oligonucleotides decreases EGFR-stimulated
MAPK signaling and cell proliferation but enhances cell migration.
Moreover, since NHERF1 has been shown to stabilize EGFR at the cell
surface and retard receptor downregulation, our study also suggests that
NHERF-1 may facilitate exclusion of Grb2 from EGFR proximity to drive
GBM migration. These results suggest that NHERF-1 functions as a novel
molecular switch that regulates the dichotomy between the migratory and
proliferative phenotypes in GBM. Elucidating the mechanism by which
NHERF-1 controls and enables GBM tumor migration and proliferation is
essential for understanding tumor cell progression and raises the possibility
of targeting NHERF-1 in tumor cells for the development of novel
anti-invasive therapies.
CB-69. THE DIFFERENTIAL EFFECT OF CONDITIONAL
DELETION OF BETA-1 INTEGRIN AND FAK ON NEURAL STEM
CELL MIGRATION FROM THE SUBVENTRICULAR ZONE
THROUGH THE ROSTRAL MIGRATORY STREAM TO THE
OLFACTORY BULB
James D. Battiste, Shyam Sirasanagandla, Elizabeth A. Maher, and
Robert Bachoo; The University of Texas Southwestern Medical Center,
Dallas, TX
The objective of this study was to investigate the role of beta-1
integrin-dependent mechanisms and Fak (a known downstream mediator
of integrin signaling) dependent mechanisms effecting adult stem cell
migration in the subventricular zone (SVZ), the rostral migratory stream
(RMS), and the olfactory bulb (OB). In the adult mammalian brain, neu-
rogenesis is restricted to the SGZ and SVZ. Neural stem cells self-renew
and produce transient amplifying progenitors that generate neuroblasts.
SVZ neuroblasts migrate a considerable distance along the wall of the
lateral ventricle and through the RMS to the OB. A critical component
of stem cells is the use of integrin receptors to communicate with extra-
cellular matrix molecules, but their precise role in migration is unclear.
This study employed a genetic strategy using a tamoxifen-inducible
Nestin-CreERT2/Rosa26-YFP reporter mouse line crossed to a either a
conditional floxed beta-1 integrin gene or a conditional floxed Fak
mouse. In beta-1 integrin deficient cells, fewer YFP-labeled cells from
the Nestin compartment were observed to migrate from the SVZ to the
OB compared to wild type. Some YFP-labeled beta-1 integrin deficit
cells were also observed to aberrantly migrate to the adjacent cortex.
However, in the Fak deficient cells, a similar number of YFP labeled
cells migrated from the SVZ to the OB. Taken together, our data show
that Beta-1 integrin is necessary for adult progenitor cell migration from
the SVZ to the OB; downstream signaling appears not to involve Fak.
Beta-1 integrin restricts neuroblast migration to the confines of the
RMS. Understanding molecular mechanisms of progenitor cell migration
in the RMS may provide crucial insight into strategies adopted by
malignant glioma cells.
CB-70. ASYMMETRY-DEFECTIVE OLIGODENDROCYTE
PROGENITORS ARE GLIOMA PRECURSORS
Sista Sugiarto1, Anders Persson1, Elena Gonzalez Munoz2,
Markus Waldhuber3, Scott Vandenberg4, William Stallcup5, Joanna Philips1,
Mitchel S. Berger1, Gabriele Bergers1, William A. Weiss1, and
Claudia Petritsch1; 1UCSF, San Fransciso, CA; 2Michigan State University,
East Lansing, MI; 3MorphoSys AG, Munich, Germany; 4UCSD, San Diego,
CA; 5Burnham Institute, San Fransciso, CA
Postnatal oligodendrocyte progenitors self-renew, generate mature oligo-
dendrocytes, and are a cellular origin of oligodendroglioma. The mechanism
for the neoplastic transformation of NG2+ oligodendrocyte is largely
unknown. Using novel cell culture and in vivo assays, we show that
normal murine and non-neoplastic human oligodendrocyte progenitors
undergo asymmetric cell divisions. To achieve asymmetric cell division,
they segregate the proteoglycan NG2 asymmetrically during oligodendrocyte
progenitor mitosis to generate cells of distinct fate. By analyzing
NG2-dificient oligodendrocyte progenitor cells, we found that the NG2+
progeny undergoes EGF-dependent self-renewal, which depends on
endogenous NG2 expression. In contrast, the NG2- progeny differentiates.
In a mouse model for oligodendroglial tumors, the S100beta-verbB p53
deleted mice, increased symmetric oligodendrocyte progenitor divisions
coincide with abnormal self-renewal rather than differentiation at premalig-
nant stages and leads to neoplastic transformation. Asymmetric cell divisions
are prevalent in NG2+ cells from human non-neoplastic tissue but not from
low-grade oligodendrogliomas, which misexpress regulators of asymmetric
cell division. Taken together, we unraveled loss of asymmetric division in
premalignant, aberrantly self-renewing, differentiation-defective murine oli-
godendrocyte progenitors and human NG2+ oligodendroglioma cells,
thereby explaining initial steps by which oligodendrocyte progenitors trans-
form into oligodendroglioma cells. Our data suggest that asymmetric cell
divisions maintain homeostasis in the postnatal oligodendrocyte lineage. In
contrast, loss or disruption of asymmetric cell division might be causal to
the neoplastic transformation of oligodendrocyte progenitor cells and
provide novel points of disruption to which specific glioma therapies can
be targeted.
Abstracts
NEURO-ONCOLOGY † N O V E M B E R 2 0 1 1 iii25
 at O
lson L
ibrary, N
orthern M
ichigan U
niversity on O
ctober 15, 2014
http://neuro-oncology.oxfordjournals.org/
D
ow
nloaded from
 
